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ABSTRACT 
 
In this thesis we have studied the signaling pathways involved in HNE-induced 
apoptotis and the effect of resveratrol in signal transduction mechanisms leading to 
apoptosis in 3T3 fibroblasts when exposed to 4-hydroxynonenal (HNE).  
 The results demonstrate the ability of HNE to induce apoptosis and ROS 
formation in a dose-dependent manner. In order to get insight into the mechanisms of 
apoptotic response by HNE, we followed MAP kinase and caspase activation pathways; 
HNE induced early activation of JNK and p38 proteins but downregulated the basal 
activity of ERK 1/2. We were also able to demonstrate HNE-induced release of 
cytochrome c from mitochondria, caspase-9 and caspase-3 activation. Resveratrol 
effectively prevented HNE-induced JNK and caspase activation hence apoptosis, as 
well as the formation of ROS. Activation of AP-1 along with increased c-Jun and 
phospho-c-Jun levels could be inhibited by pretreatment of cells with resveratrol. 
Additionally, overexpression of dominant negative c-Jun and JNK1 in 3T3 fibroblasts 
prevented HNE-induced apoptosis, which indicates a role for JNK-c-Jun/AP-1 pathway. 
Moreover, HNE induced decreased Bcl-2 and increased Bax, Bak and Bim protein 
levels, which could be prevented by resveratrol. 
 
In light of the JNK-dependent induction of c-Jun/AP-1 activation and the 
protective role of resveratrol, these data indicate a critical potential role for JNK in the 
cellular response against toxic products of lipid peroxidation.  Resveratrol also prevents 
modulation of Bcl-2 proteins and formation of ROS by HNE.  In this respect, resveratrol 
acting through MAP kinase and Bcl-2 protein pathways in addition to act as 
antioxidant-quenching reactive oxygen intermediates is a potential small molecule 
against apoptosis-related human pathologies. 
 
vÖZET 
 
Bu tezde 3T3 fibroblast hücrelerinde 4-hidroksinonenal (HNE) taraf0ndan 
indüklenen apoptotik sinyal ileti yolaklar0n0n ve resveratrol’ün bu yolaklar0n üzerine 
etkisinin ortaya konulmas0 için yap0lan çal07malar sunulmu7tur.  
 Elde edilen sonuçlar HNE’nin doza ba80ml0 olarak apoptosise ve oksidatif stres 
olu7umuna yol açt080n0 göstermi7tir. HNE taraf0ndan indüklenen apoptosis 
meknizmalar0 derinlemesine incelenmi7, HNE’nin JNK ve p38 proteinlerinin 
aktivasyonuna ve ERK 1/2 proteininin inhibisyonuna yol açt080 ortaya konulmu7tur. 
HNE’nin ayn0 zamanda mitokondriden sitokrom c sal0n0m0na, kazpaz-9 ve kazpaz-3 
aktivasyonunu sa8lad080 gözlenmi7tir. Resveratrol’ün HNE taraf0ndan indüklenen JNK 
ve kazpaz aktivasyonunu ve oksidatif stres olu7umunu engelledi8i ortaya konulmu7tur. 
AP-1 aktivasyonu, c-Jun ve fosforile-c-Jun proteinlerinin HNE ile indüklenen art070 da 
resveratrol taraf0ndan engellenmi7tir. Dominant negatif c-Jun ve JNK1 
overekspresyonlar0 da HNE taraf0ndan indüklenen apoptosisi önlemi7tir, böylece JNK-
c-Jun/AP-1 yola80n0n bu süreçteki rolü ortaya konulmu7tur. Ek olarak HNE Bcl-2 
proteininde azalmaya ve Bax, Bak Bim proteinlerinde artmaya yol açm07t0r, bu etkiler 
de resveratrol taraf0ndan önlenmi7tir.  
JNK’a ba80ml0 c-Jun/AP-1 aktivasyonu ve resveratrol’ün koruyucu rolü 07080nda elde 
edilen sonuçlar  JNK’0n lipid peroksidasyon toksik ürünlerine hücresel cevapta kritik 
bir rol üstlendi8ine i7aret etmektedir. Resveratrol antioksidan özelliklerine ilaveten  
MAP kinazlar ve Bcl-2 proteinleri üzerinden gösterdi8i etkilerle apoptosise ba80ml0
olarak geli7en hastal0klar için önemli bir potansiyel küçük moleküldür. 
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To my family, 
past, present and future… 
 
Shoot for the moon. Even if you miss, you will land among the stars. 
 
Les Brown 
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1CHAPTER 1 
 
1 INTRODUCTION 
 The presence of all human societies is determined by birth, death, and disease. 
Throughout the history of world, illness has often been attributed to the will of the gods 
and faith until the rise of positivist scientific medicine along with other revolutions in 
18th century. The first written materials on medicine were discovered in an ancient 
Egypt papyrus, dated around 1536 BC (Figure 1.1) [230]. Furthermore, the ancient 
Greek physician and philosopher Hippocrates developed the first methodical approach 
towards examination, diagnosis, treatment and prognosis in 400 BC. The Endeavour of 
medicine through out centuries kept going despite the ethical, religious and economical 
hindrance. Ignaz Philipp Semmelweis, a Hungarian-Austrian physician, managed to 
reduce the death rate of women related to childbirth by simply introducing “wash your 
hands before attending to women in childbirth” in 1847, an initial theory of antisepsis 
[231].  Joseph Lister, Robert Koch and Louis Pasteur, developed novel therapeutic and 
preventive approaches against infectious diseases, further developed this theory [232]. 
The new concept of “cause-disease” relationship continued to be constructed and the 
progress in surgery and pharmacological sciences in the 20th century had a great impact 
on general public health, which revolutionized the practice of medicine. Today the new 
era of genomics and proteomics facilitate the progress of medicine and transformation 
of clinical practice along with molecular and genetic characterization of disease 
pathogenesis. The impact of increasing resources devoted to basic research enable rapid 
translation of molecular findings to clinical field: bench to bedside.  
 Oxidative modification of biolipids has prominent consequences in the 
pathogenesis of human pathologies. In addition to massive in vivo oxidative 
modification and deposition of lipids, lipid peroxidation end-products may act as 
secondary messengers in cellular signaling pathways [1]. Regulation of cellular function 
takes place through a network of intracellular and extracellular signaling cascades and 
2the physiological or pathological outcome is defined by the duration, amplitude, 
intensity and nature of these signaling pathways. Oxidized low-density lipoproteins 
(Ox-LDLs) and other lipid peroxidation end products interfere with various signaling 
pathways including G-protein coupled receptors, protein kinase C and D, NF-B and 
MAP kinases [1-3]. Aldehydes have been defined as one of the most significant among 
the various end products of the oxidative breakdown of biomembrane polyunsaturated 
fatty acids [4]. 4-hydroxynonenal (HNE), one of the major aldehydic products of the 
peroxidation of membrane w-6 polyunsaturated fatty acids, has been demonstrated to be 
present in the pathogenesis of many human diseases such as atherosclerosis, cancer, 
neurodegenerative disorders and diabetes [5-7].  Nevertheless, the molecular targets and 
the mechanisms of their activation by oxidized lipids, specifically by HNE, remain 
largely unknown. Moreover, considering the involvement of apoptosis (programmed 
cell death) as a common molecular process in all these diseases, it would be convenient 
to explore the mechanisms of 4-HNE-induced apoptosis, if any. 
 
Figure 1.1 Ancient Egyptian medicine. Homer in the Odyssey remarked,  
“In Egypt, the men are more skilled in Medicine than any of human kind” [230]. 
3Apoptosis is an essential and evolutionary conserved process for normal 
embryogenesis, organ development, tissue homeostasis and elimination of deleterious 
cells from multicellular organisms (Figure 1.2). Any deregulation or aberrant activation 
of apoptosis can be involved in the pathogenesis of human diseases such as 
atherosclerosis, chronic heart failure, cancer, diabetes and neurodegenerative disorders 
[8,9]. Thus, the cellular and genetic integrity of a cell under stress or oncogenic stimuli 
should be strictly controlled by cellular signaling pathways to maintain its functionality 
and viability. Gene expression, post-translational protein modifications and protein-
protein interaction modules mainly mediate the regulation of apoptosis at cellular level. 
Protein phosphorylation is a main protein modification and is executed by 
phosphotransferase enzymes designated as kinases.  Mitogen-activated protein kinases 
(MAP kinases) are a group of protein serine/threonine kinases that are differentially 
activated in response to a variety of pro- or anti-apoptotic stimuli [10]. In combination 
with several other signaling pathways, they can differentially alter phosphorylation 
status of the transcription factors, suxh as c-Jun/AP-1 [10]. Three major types of MAP 
kinase cascades have been reported in mammalian cells that respond synergistically to 
different upstream signals: c-Jun N-terminal kinase/stress activated protein kinase 
(JNK), extracellular signal-regulated kinases 1/2 (ERK 1/2) and p38 [10]. It is important 
to recognize that these kinases are essential for many physiological functions and 
spatiotemporal dysregulation of these kinases has been proposed to be involved in 
common human pathologies. Thereby, regulation of kinase function with small 
molecule approach (either de novo synthesized or natural products) has been implicated 
as a promising approach for rational disease treatment.  
 
Apoptosis is executed by caspases, which are cysteine-directed aspartate 
proteases, cleaving their substrates on the carboxyl side of an aspartate residue. Intrinsic 
apoptosis signaling pathways mainly intersect at mitochondria and following 
mitochondrial loss of integrity, cytochome c is released into the cytosol. This 
translocation of cytochrome c has been followed by formation of an apoptosome 
complex and activation of caspase-9, which is an essential component of apoptotic 
machinery [11]. Recent research advances in apoptosis research provided us a new 
protein family member: Bcl-2 proteins [12]. The Bcl-2 proteins consist of a protein 
family related through their conservation of helical sequences known as Bcl-2 
homology (BH) domains. These proteins are known to modulate mitochondrial function 
4and regulate the release of activating factors of apoptosis, such as cytochrome c, from 
mitochondria and each Bcl-2 family member contain at least one of four BH-domains, 
BH1-BH4 [12]. Modulation of Bcl-2 proteins either at gene expression level or at post-
translational level determines the pro- or anti-apoptotic response. Bcl-2 proteins, 
together with upstream kinases and their targets, are key checkpoints and determinants 
for the cellular response to stress.  
 
Figure 1.2 Apoptosis: an ancient Greek word used to describe the "falling off" of petals 
from flowers or leaves from trees (from the courtesy of U.S. National Library of 
Medicine, http://ghr.nlm.nih.gov, 2006) 
 
In this study our aim was to characterize the pro-apoptotic signaling pathways 
involved in HNE-induced apoptosis in 3T3 fibroblasts and studying the potential 
protective role of resveratrol, which is a phytoestrogen widely distributed in nature and 
highly found in grape skin and seed, mulberries and peanuts. For this purpose, we 
characterized the dose and time kinetics of HNE-induced apoptosis and investigated the 
involvement of mitochondrial apoptosis pathway, including cytochrome c release in this 
process. Since the protective effect of resveratrol on HNE-induced apoptosis has not 
been studied before, we have also studied the effect of resveratrol on HNE-induced 
apoptosis and oxidative stress. Furthermore, HNE-induced apoptosis signaling 
pathways, involving MAP kinases, c-Jun/AP-1 transcription factors, caspases and Bcl-2 
5protein members were explored and the modulation of these pathways by resveratrol 
was investigated.  This is the first study, which describes a complete picture of signaling 
pathways involved in HNE-induced apoptosis and molecular targets of resveratrol 
against cellular stress.  
 
A chapter for the background follows this introductory section, which involves 
current perspectives of this research. This background chapter is followed by Chapter 3, 
which explains materials and methods utilized in this study in a detailed fashion. The 
results are presented in Chapter 4 along with the figures explaining experimental 
findings. The results are discussed in Chapter 5 in the light of current literature. The 
final Chapter 6 involves a brief synopsis and conclusions of this study along with future 
perspectives.  
 
6CHAPTER 2 
 
2 BACKGROUND 
 2.1 Apoptosis 
2.1.1 Historical Perspective 
 Apoptosis is of Greek origin, having the meaning "falling off or dropping off", in 
analogy to leaves falling off trees or petals. Already since the mid-nineteenth century, 
many observations have indicated that cell death plays a considerable role during 
physiological processes of multicellular organisms, particularly during embryogenesis 
and metamorphosis [13,14]. The first notion of programmed cell death in physiological 
conditions was first identified in the neuronal system of developing toad embryos [15]. 
The term programmed cell death was introduced in 1964, proposing that cell death 
during development is not of accidental process but follows a sequence of controlled 
steps leading to locally and temporally defined self-destruction [16]. Eventually, Kerr et 
al. introduced the term apoptosis to describe the morphological processes leading to 
controlled cellular self-destruction [17]. Considering the last thirty years of apoptosis 
research, the key steps for making the decision of a cell to either live or to die and main 
components of mammalian apoptotic machinery have been identified. These essential 
findings of basic science would certainly allow the development of novel therapeutic 
strategies and tools for treatment of major human diseases with an etiology of apoptosis 
dysfunction. 
 
72.1.2 Apoptosis Pathways 
 
As described above, apoptosis is an essential and evolutionary conserved process 
for normal embryogenesis, organ development, tissue homeostasis and elimination of 
deleterious cells from multicellular organisms. Any deregulation or aberrant activation 
of apoptosis can be involved in the pathogenesis of human diseases such as 
atherosclerosis, chronic heart failure, cancer, diabetes and neurodegenerative disorders 
[8,9]. Thus, the cellular and genetic integrity of a cell under stress or oncogenic stimuli 
have to be strictly controlled to maintain its functionality and viability. The cells are 
absolute targets for various extrinsic and intrinsic stimuli and they receive and process 
signals not only from the plasma membrane but also from different compartments 
within cytoplasm. This dynamic characteristic of cells enables them to sense signals and 
response quickly, a fundamental principal of cellular survival. Multiple death and 
survival signals are integrated to molecular apoptotic machinery via protein signaling 
networks, which are predominantly regulated by protein-protein interactions, subcellular 
localization and major protein modifications such as phosphorylation and cleavage. 
Mostly an array of protein kinase-mediated pathways targets “the players” of apoptotic 
machinery at transcriptional and post-translational level and regulates their level and/or 
function.  The balance between pro- and anti-apoptotic signaling pathways determines 
the fate of a cell in response to an external or internal stimulus.    
 
Apoptosis is a multi-component programmed cell death process, which is 
characterized by specific cellular morphological patterns such as chromatin 
condensation, nuclear fragmentation, cytoplasmic shrinkage, membrane blebbing, 
formation of apoptotic vesicles and consequent phagocytosis by immune cells [18]. The 
molecular changes that occur during apoptosis are redistribution of phosphotidylserine 
at outer and inner leaflets of plasma membrane and internucleosomal DNA cleavage. 
Apoptosis is usually induced by an initiation phase, which depends tightly on the cell 
type and the characteristic of the stimuli (origin, duration, amplitude and presence of co-
stimuli). In a cell under an apoptotic insult either within or outside of the cell, multiple 
cellular signalling modules are activated synchronously. During this deterministic 
phase, molecular signaling modules serve as parts of central apoptotic machinery, which 
should be tightly controlled and finely tuned to maintain appropriate biochemical 
functioning of the cell.  
8Caspases are the main executioners of programmed cell death process and their 
mechanism of activation is first characterized in Caenorhabditis elegans [19]. In this 
model four gene products (CED-3, CED-4, CED-9 and EGL-1) are playing fundamental 
roles in the apoptosis process. The interaction between caspase protein, CED-3 and an 
adaptor-protein, CED-4 leads to formation of a complex defined as an “apoptosome”, in 
which CED-3 zymogen is activated through close proximity and self-processing. CED-4 
is sequestered and kept away from CED-3 via its interaction with a mitochondria-
associated protein, CED-9 in unstimulated cells. In response to a death stimulus, a Bcl-2 
homolog protein with a BH3 domain, Egl-1 is induced and interacts with CED-9, which 
frees CED-4 and formation of apoptosome as well as activation of CED-3 [19]. This 
simple and clear caspase activation model is evolutionary conserved. Caspases are also 
normally inactive or minimally active in unstimulated healthy mammalian cells and 
they are activated through a set of signaling events such as activation of a death receptor 
or a direct DNA damage by chemotherapeutics. However, there is one main difference; 
the apoptotic machinery becomes much more complex throughout evolution in parallel 
to increased complexity of the organisms at biochemical, molecular and physiological 
levels. Thereby, the molecular apoptotic signaling mechanisms in mammalian cells have 
been a subject of intensive studies for the past few decades and two main components 
with distinct and overlapping parts have been identified (Figure 2.1): 
i. an extrinsic pathway which involves direct initiator cascades triggered by 
death receptors on cell surface 
 
ii. an intrinsic pathway which involves mitochondria and intracellular death 
signals  
 
These two pathways share a couple of adaptor proteins, proteases, protein kinases and 
protein phosphatases as a part of apoptotic signaling modules, but the potential 
intersections between these pathways which controls life and death decisions of a cell 
are not completely identified, yet.   
 
9Figure 2.1 Basic overview of apoptosis pathways. 
 
The extrinsic or death receptor-mediated pathway is activated in response to 
extracellular pro-apoptotic signals and integrated to the apoptotic machinery via specific 
death receptor adaptors (Figure 2.2). The death receptor family members are 
characterized by the presence of cysteine-rich repeats in their extracellular domains and 
protein-protein interaction modules known as the death domain (DD) in their 
cytoplasmic portions [20]. Binding of specific ligands induces receptor multimerization 
and formation of a signaling complex known as DISC (death inducing signaling 
complex), which is consist of various adaptor proteins including TRADD, FADD, 
Daxx, RIP, RAIDD and FLIP [20]. FADD acts as a bridge between DISC and caspase-
8, which is critical for recruitment and oligomerization of caspase-8 in the DISC, as 
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well as autocatalytic activation caspase-8 and activation of death receptor-mediated 
programmed cell death [21-23]. 
 
Figure 2.2 Detailed scheme of apoptosis pathways. 
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The direct activation of effector caspases-3 and -7 by caspase-8 may not 
necessarily involve mitochondrial events; however in some cell types death receptor-
mediated apoptotic signaling requires a mitochondrial death amplification loop 
[21,24,25]. The reason for this discrimination has not been identified clearly, but 
insufficient amount of active caspases or abundance of downstream inhibitors of 
apoptotic machinery was suggested to be involved in this paradigm. The mitochondrial 
amplification loop involves the caspase-8-mediated cleavage of the cytosolic BH3-only 
pro-apoptotic Bcl-2 family member Bid; an integration of two apoptotic pathways on 
mitochondria. Upon processing by caspase-8, Bid translocates from cytosol to 
mitochondria where it oligomerizes with pro-apoptotic Bcl-2 family members Bax and 
Bak and mediates cytochrome c release [14,25,26]. The cytosolic cytochrome c induces 
the formation of the apoptosome complex, which is composed of seven Apaf-1 
(Apoptotic protease activating factor-1) molecules, each bound to one molecule of 
cytochrome c and a dimer of caspase-9. Formation of apoptosome results in the 
activation of caspase-9, which thereby activates effector caspases 3 and 7 to initiate the 
execution of apoptosis [25,26]. The intracellular components that convey apoptotic 
stimuli to central apoptotic machinery are not identified completely, but there is one 
reality that has been shown clearly; mitochondria lie in the center of apoptotic 
machinery. 
 
The intrinsic apoptosis pathway, which involves direct and active contribution of 
mitochondria, is initiated by receptor-independent apoptotic stimuli such as DNA-
damaging agents, UV and -radiation, hypoxia and growth factor withdrawal [27-29]. 
These stimuli target intracellular signalling components, which transmit the apoptotic 
signal to main apoptotic machinery. In mammalian cells, Bcl-2 family proteins are one 
of the main “apoptotic sensors” mentioned above and they act primarily on the 
mitochondria, where they regulate the survival or death signals in a preventive or 
provocative fashion. Upon exposure to apoptotic insults many apoptosis regulator 
proteins such as cytochrome c, SMAC (second mitochondria-derived activator of 
caspases)/DIABLO (direct inhibitor of apoptosis-binding protein with low pI) and 
Omi/HtrA2 (high-temperature-requirement protein) are released from mitochondria 
(Figure 2.2) [30,31]. Some proteins responsible for caspase-independent DNA 
fragmentation and apoptosis-like nuclear morphology (apoptosis inducing factor (AIF) 
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and endonuclease G) are also released from mitochondria following apoptotic stimuli 
[32]. Thus, mitochondrial integrity is critical for maintaining cellular homeostasis and 
proper compartmentalization of apoptotic mediators. The mechanisms for the intrinsic 
apoptosis pathway and induction of mitochondrial permeabilization are not completely 
understood, but studies until today provide some clue how apoptotic stimuli induce 
permeabilization of mitochondrial membranes.  
 
2.1.3 Bcl-2 protein family 
2.1.3.1  Multidomain anti-apoptotic Bcl-2 proteins 
 
The Bcl-2 family proteins can be classified into three groups based on their 
structural and functional properties (Figure 2.3). The first group involves the 
multidomain anti-apoptotic members Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1/Bfl-1, Boo/Diva 
and NR-13. They exhibit all four Bcl-2 homology domains (BH1-4) which are essential 
for their survival function through mediating protein-protein interactions and a 
transmembrane domain, which is formed by a stretch of hydrophobic amino acids near 
their C-terminal.  The C-terminal domain is required for anchoring or insertion in 
cellular membranes of not only mitochondria but also nucleus and endoplasmic 
reticulum [33,34]. The -helices of BH1, BH2 and BH3 domains form a hydrophobic 
pocket and the N-terminal BH4 domain further stabilizes this structure [35,36]. The 
protein structure of Bcl-xL complexed with the BH3 domain of Bak suggested a 
functional interaction of amphiphathic -helix of Bak BH3 with the hydrophobic 
groove formed by BH1-3 domains of Bcl-xL [37].  Both BH3-only and multidomain 
pro-apoptotic Bcl-2 proteins appear to act through exposure of their BH3 domain 
following an apoptotic insult [38,39]. Therefore, this protein-protein interaction model 
proposed anti-apoptotic Bcl-2 members as functional traps of pro-apoptotic members, 
but is the cellular machinery always in a pro-apoptotic conditioning, which should be 
continuously blocked by anti-apoptotic Bcl-2 members? Or is it the pro-apoptotic 
members, which are present ubiquitously in the local cellular compartments, acting pro-
actively to sequester the “silencers” of apoptotic machinery along with apoptotic 
process going by the way? Even though the exact biochemical mechanisms for the 
actions of anti-apoptotic Bcl-2 members remain to be elucidated, the efforts to clarify 
these mechanisms provided us many clues. Bcl-2 has been shown to modulate cellular 
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viability through regulating intracellular calcium homeostasis, cellular redox state, lipid 
peroxidation, as well as cytochrome c release from mitochondria [40-42]. Bcl-2 has 
been shown to attenuate apoptosis induced not only by ionizing radiation, 
chemotherapy, UV radiation but also by death receptors [28,43,44]. Overexpression of 
Bcl-2 protects SW480 cells from TRAIL-induced apoptosis via attenuation of caspase-8 
activation and cleavage of Bid and caspase-3 [45]. In contrast, Fas/FasL-, TRAIL- and 
TNF-mediated apoptosis pathways have been proposed to be insensitive to blockage 
by Bcl-2/Bcl-xL [46,47]; thereby the exact contribution of Bcl-2/Bcl-xL in receptor-
mediated extrinsic apoptotic pathway remains undetermined. Mice deficient in Bcl-2 
have been demonstrated to have gray hair, polycystic kidneys and decreased number of 
lymphocytes [48]. Mice deficient in Bcl-xL die at around day 13 of gestation due to 
massive neuronal and hematopoetic apoptosis [49]. Bcl-2 and Bcl-xL were also reported 
to abrogate mitochondrial translocation and oligomerization of Bax in the outer 
mitochondrial membrane [50,51].   
 
The mechanistic insight, which is derived from cases characterized with Bcl-2 
overexpression, remains insufficient to explain the consequences of Bcl-2 on resistance 
to apoptosis. In addition to level of expression, post-translational modifications such as 
such as phosphorylation and cleavage may regulate the activity of Bcl-2 and Bcl-xL. 
Phosphorylation of Bcl-2 at Ser-70 by PKC has been reported to be required for 
efficient anti-apoptotic function [52]. In contrast, microtubuli-targeting agents such as 
paclitaxel have been shown to induce hyperphosphorylation of Bcl-2 (Ser-70, Ser-87 
and Thr-69) and abrogate its anti-apoptotic effect [53]. Phosphorylation of Bcl-xL at 
Ser-62 by JNK (c-Jun N-terminal kinase) in response to taxol or 2-methoxyestradiol 
treatment has been reported to oppose the anti-apoptotic function of Bcl-xL and 
sensitizes prostate cancer cells to apoptosis [54]. The caspase-dependent N-terminal 
cleavage of Bcl-2/Bcl-xL and exposure of their BH3 domains converts these anti-
apoptotic proteins into pro-apoptotic ones.   
 
2.1.3.2 The multidomain pro-apoptotic members of Bcl-2 protein family 
 
This second group of Bcl-2 protein family mainly involves Bax, Bak and Bok/Mtd 
(Figure 2.3). Bax is mainly localized in the cytosol or loosely attached to the outer 
membrane of mitochondria or ER as a monomer.  Following an apoptotic stimuli, Bax 
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undergoes a unique conformational change exposing its C-terminal hydrophobic 
domain, which is involved in its anchorage to mitochondrial membrane [55]. In the 
mitochondrial membranes, Bax forms dimers, oligomers or high-order multimers [56]. 
Another important multidomain proapoptotic Bcl-2 protein family member is Bak, 
which is an integral protein of outer mitochondrial membrane and ER. Similar to Bax, 
Bak also undergoes a conformational change -the open conformer- in response to 
apoptotic stimuli such as etoposide and cisplatin [57,58]. The inhibitory effect of Bcl-2 
on Bak acts through selective interaction of Bcl-2 with open conformer (N-terminal 
exposed conformation) of Bak [59]. The principles of these conformational changes and 
oligomerization of Bak and Bax proteins remain to be explained at structural level. The 
involvement of Bak and Bax in apoptosis regulation is demonstrated by the insensitivity 
of Bak -/- Bax -/- MEFs to multiple apoptotic stimuli including chemotherapeutics and 
UV radiation [60]. Afterwards, the requirement of Bak and Bax in the apoptotic 
machinery has been confirmed many other studies. Bax-null cells have been shown to 
be resistant against TRAIL-induced apoptosis [61]. Bax deficiency did not effect the 
processing of caspase-8 or Bid cleavage by TRAIL, but the release of Smac/DIABLO, 
which is required for inhibition of IAP proteins and caspase-3 activation, was abrogated 
[61]. In TRAIL-resistant leukemic cells that are deficient in Bax and Bak, release of 
mitochondrial proteins appear to be abrogated and adenoviral transduction of the Bax, 
but not the Bak gene, to the Bax/Bak-deficient leukemic cells rendered them TRAIL-
sensitive as assessed by enhanced apoptotic death and caspase-3 processing [62]. 
Recently activation of multiple caspases by DNA damage and ER stress has been shown 
to be directly regulated by Bax and Bak in double knock-out MEFs [63]. Post-
translational modifications of Bax or Bak such as cleavage have been shown to regulate 
the functional impact of these proteins on apoptosis. 
 
Calpain-mediated conversion of Bax into a truncated form (arises from cleavage 
of N-terminal 33 amino acids, p18 Bax) enhances its pro-apoptotic properties of the 
protein upon stimulation with chemotherapeutics [64]. After truncation into its p18 
form, Bax behaves like a BH-3 only protein and the potentiation of apoptosis by p18 
Bax has been proposed to be related to increased affinity for Bcl-xL. Furthermore, a 
cathepsin-like cysteine protease is involved in degradation of p18 Bax and stabilization 
of p18 Bax by cathepsin inhibitors enhances drug-induced apoptosis [65].  
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2.1.3.3 BH3-only members of Bcl-2 protein family 
 
The third group of the family involves BH3-only proteins such as Bid, Bad, Bim, 
Bik, Blk, Hrk, BNIP3, Nix, BMF, Noxa and Puma. These proteins share only the 
amphipathic -helical BH2 homology domain and mainly act through inhibition of Bcl-
2/Bcl-xL and activation of Bak and Bax. They act as sentinels of cell death sensing 
machinery and in a point of view; they coordinate the fine-tuning of apoptotic response 
through their interactions with pro- and anti-apoptotic Bcl-2 members.  This fine-tuning 
phenomenon has been attributed to the selective predisposition of certain BH3-only 
proteins for either anti-apoptotic or pro-apoptotic Bcl-2 proteins, but the definitive 
mechanisms that lie behind remain to be clarified [66]. There are two main pathways, 
which characterize the function of BH3-only proteins on mitochondria; 
 
i) Direct activators: Some BH3-only members (Bid and Bim) interact with pro-
apoptotic Bcl-2 proteins such as Bak and Bax and thereby induce their 
activation/oligomerization. This type of activity of BH3-only proteins can be 
attenuated by Bcl-2 through selective sequestration and functional silencing. 
 
ii) Sensitizers: Other BH3-only members (Bad) interact with anti-apoptotic Bcl-2 
proteins and prevent them binding and sequestering BH3-only members such as 
Bid and Bim, which can activate Bak and Bax. 
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Figure 2.3 Bcl-2 protein family members are key regulators of apoptosis. 
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The functional regulation of BH3-only proteins at cellular level could be regulated by; 
 
1) Phosphorylation  
 
Selective phosphorylation of proteins at different residues may modulate different 
molecular and cellular responses. Considering apoptosis signalling and Bad 
phosphorylation, survival signals induce phosphorylation of Bad on Ser-112, Ser-136, 
and Ser-155, which leads to the sequestration and inactivation of Bad by 14-3-3 
proteins [67,68]. Recently, a novel Cdc2- or JNK-mediated phosphorylation site of Bad 
has been mapped at Ser-128 and this modification has been demonstrated to inhibit 
sequestration of Bad by members of 14-3-3 family and potentiate its pro-apoptotic 
effect [69,70]. Cytokine-dependent phosphorylation of Ser-170 has been demonstrated 
to negatively regulate pro-apoptotic activity of Bad [71]. Furthermore, phosphorylation 
of Bim at Ser-65 by JNK has been shown to mediate trophic factor withdrawal-induced 
Bax-dependent apoptosis [72].  
 
2) Transcriptional control  
 
Puma (p53 up-regulated modulator of apoptosis) and Noxa are transcriptional 
targets for p53 [73,74]. PUMA is transcriptionally induced by the chemotherapeutics 5-
FU and adriamycin in a p53-dependent fashion and it is localized to mitochondria 
where it interacts with Bcl-2 and Bcl-XL through its BH3 domain [75]. In contrast to 
Noxa, the pro-apoptotic effect of Puma has been shown to depend on conformational 
change and multimerization of Bax [76].  Induction of Noxa did not show any 
relevance to subcellular localization of Bax, but it selectively interacts with Bcl-2, Bcl-
xL and Mcl-1 via its BH3-only domain [74].   
 
3) Cleavage  
 
Following death receptor signalling, the full-length 22 kDa Bid is cleaved within 
its unstructured loop and a 15 kDa truncated form of Bid is created, tBid [77,78]. 
Cleavage of Bid results in exposure of a new terminal glycine residue, which is N-
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myristoylated [79]. Upon N-myristoylation, tBid is selectively routed to mitochondria 
and induces oligomerization of Bax and Bak. 
 
2.1.4 Mitogen-activated protein kinases, AP-1 and apoptosis regulation 
 
2.1.4.1 MAP kinase signaling pathways 
 Living cells can sense and respond to biological and chemical alterations, which 
may affect different cellular functions such as proliferation, migration, differentiation 
and cell death. The cellular response to stress depends on the type, strength and duration 
of the stimuli and involves a complex network of signal-transduction pathways. 
Mitogen-activated protein kinases (MAP kinases) are among the best-
characterized signaling pathways regulating cell survival and apoptosis. MAP kinase 
signaling cascade consists of a module of three cytoplasmic kinases: a mitogen-
activated protein (MAP) kinase kinase kinase (MAPKKK), a MAP kinase kinase 
(MAPKK) and a MAP kinase (MAPK) itself (Figure 2.4). MAPK cascades regulate 
proliferative and cellular stress signals into changes in protein interactions and/or gene 
expression. MAPKKKs are serine-threonine kinases that receive activating signals and 
then activate its substrate, a MAPKK, by phosphorylation. MAPKKs are dual-
specificity kinases with ability to phosphorylate serine and threonine residues in their 
substrates, MAP kinases. MAP kinases are serine-threonine kinases, which 
phosphorylate both cytoplasmic and nuclear substrates. Transcription factors such as 
AP-1 are among direct targets of MAP kinases. 
 
In mammals, three main MAP kinases are identified: extracellular signal regulated 
kinase (ERK), p38 and c-Jun NH2-terminal protein kinase/stress activated protein 
kinase (JNK/SAPK) groups of MAPKs [80]. 
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Figure 2.4 MAP kinase signaling pathways (adapted from [10]). 
 
These different MAP kinases are regulated by distinct stimuli. JNK and p38 are 
mainly activated by cellular stress and by inflammatory cytokines. In contrast, the ERK 
signaling pathway is activated by mitogens and growth factors, and transduces survival, 
proliferation and differentiation signals. MAP kinases exert a selective substrates 
specifity, which  are involved in the regulation of specific components of transcription 
factor AP-1. For example, c-Jun is phosphorylated by JNK, c-Fos is a substrate for ERK 
while ATF-2 can be phosphorylated by both JNK and p38 [80]. AP-1 is a major 
transcription factor complex composed mainly by homodimers of c-Jun and 
heterodimers of c-Jun/c-Fos [81]. AP-1 transcriptional activity may be related to either 
apoptosis or proliferation in different cellular systems. The outcome of AP-1-mediated 
transcriptional activity in response to mitogens or cellular stress has been proposed to be 
defined by the composition of dimers forming AP-1 transcription factor complex. 
 
A major target of the JNK signaling pathway is activation of a transcription factor, 
AP-1, which is mediated by phosphorylation of c-Jun. JNK binds to the NH2-terminal 
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activation domain of c-Jun and phosphorylates it on Ser-63 and Ser-73, resulting in 
increased transcriptional activity of AP-1 [82,83]. The other major substrates are 
transcription factors: activating transcription factor (ATF)-2 and Elk-1 [84]. JNK 
appears to be essential for AP-1 activation caused by stress and some cytokines, but is 
not required for AP-1 activation in response to other stimuli [85]. Thus, the precise role 
of AP-1 in the response to JNK activation is not clear and is likely to be modified by the 
activity of other transcription factors that interact with AP-1 on the promoters of target 
genes.   
 
The JNK protein kinases are encoded by three genes. The Jnk1 and Jnk2 genes are 
expressed ubiquitously whereas Jnk3 expression is limited to brain, heart and testis. 
These genes are alternatively spliced resulting in at least ten JNK isoforms. Mice 
deficient in JNK1 or JNK2 are morphologically normal, but are immunodeficient due to 
severe defects in T cell function. In contrast, deletion of both Jnk1 and Jnk2 genes 
causes early embryonic death [86]. MEFs isolated from Jnk1-/- Jnk2 -/- mice exhibit 
defects in AP-1 transcription activity, decreased proliferation and resistance to stress- 
induced apoptosis [86]. JNK is activated by two protein kinases, MKK4 (SEK1) and 
MKK7 (Figure 2.4). Although MKK4 and MKK7 are dual specificity kinases and can 
phosphorylate JNK on both Tyr and Thr. MKK4 and MKK7 appear to selectively 
phosphorylate JNK on Tyr and Thr, respectively. The difference in specificity suggests 
that MKK4 and MKK7 may act cooperatively to activate JNK [87]. In addition to 
MEKKs, several other MAPKKKs have been reported to activate the JNK signaling 
pathway such as Apoptosis Stimulating Kinases (ASK1 and ASK2) and the mixed-
lineage protein kinases (MLK1-3, DLK and LZK) [87]. Involvement of MEKK1 and 
MEKK3 have been implied to be involved in cytokine- and cellular stress-induced JNK 
activation [87].  
 
ERK1 and ERK2 are widely expressed in human tissues and are involved in the 
regulation of cell cycle and proliferative functions in already differentiated cells. Many 
different stimuli, including growth factors, cytokines, viral infection, G protein-coupled 
receptor ligands, and carcinogens, activate the ERK1/2 pathway [88]. Ras proto-
oncogene may activate the downstream components of kinase module (c-Raf1, B-Raf, 
or A-Raf). Mutations that convert Ras to an activated oncogene are common oncogenic 
mutations in many human tumors. Oncogenic Ras persistently activates the ERK 1/2 
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pathway, which contributes to the increased proliferative rate of tumor cells. For this 
reason, inhibitors of the ERK pathways are entering clinical trials as potential anticancer 
agents. In differentiated cells, ERKs have different roles and are involved in responses 
such as learning and memory in the central nervous system. The ERK 1/2 signal 
transduction pathway in mammalian cells has been extensively studied. Proliferative 
signals such as growth factors induce autophosphorylation and activation of receptor 
tyrosine kinases, such as Raf. Activation of Raf results in MEK and ERK 1/2 activation 
and regulation of proliferation and cell cycle progression [89,90]. Nevertheless, ERK 
pathway is generally regarded as survival-promoting, ERK activation may mediate the 
response to various stress-inducing stimuli including genotoxins and microtubule 
inhibitors. The balance between the activities of survival-promoting pathways such as 
ERK and pro-apoptotic pathways such as JNK and p38 has been proposed to determine 
the response of a cell under stress [91].  
 
The p38 kinases were first defined in a screen for drugs inhibiting TNF-
mediated inflammatory responses. The p38 MAP kinases regulate the expression of 
many inflammatory mediators and exerts important role in activation of the immune 
response [80]. p38 MAP kinases are also activated by many other stimuli, such as 
hormones, G protein-coupled receptor ligands and cellular stress [80,92]. The p38 
kinases are activated by TAB1, which is an adaptor protein with no known catalytic 
activity. This important finding indicates that other adaptor proteins should be 
investigated for potential roles in regulating MAPK activity.  
 
The importance of MAPKs in controlling cellular responses to the environment 
and in regulating gene expression, cell growth, and apoptosis has made them a priority 
for research related to many human diseases. MAP kinase knockout phenotypes are 
summarized in Table 2.1. The ERK, JNK, and p38 pathways are all molecular targets 
for drug development, and inhibitors of MAPKs will surely be one of the new classes of 
drugs developed for the treatment of human disease. 
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Table 2.1 Summary of MAP kinase knockout phenotypes. 
 
2.1.4.2 The role of MAP kinases in apoptosis regulation 
 A finely controlled regulation of MAP kinases is required for physiological cell 
proliferation and differentiation; whereas an unregulated activation of these MAP 
kinases can result in oncogenesis or diseases related to disproportionate apoptosis. The 
role of JNK in pro-apoptotic, signaling has been investigated by identification of target 
genes induced by stress. The JNK/AP-1 pathway has been proposed to promote 
apoptosis by increasing the expression of pro-apoptotic genes such as Bak and TNF
and decreasing the expression of p53 and its target p21, which would prevent cell cycle 
arrest and promote apoptosis [93]. However, more recent studies demonstrate that JNK 
is not required for UV radiation-induced accumulation of p53 [86]. The potential role of 
p53 as a target of JNK signaling is therefore unclear. JNK has also been observed to 
increase expression of Fas-L [94].  However, murine embryo fibroblasts prepared from 
Jnk1-/- and Jnk2-/- embryos (Jnk null MEFs) exhibit no defects in Fas-induced apoptosis, 
indicating that JNK is not required for Fas- mediated apoptosis but it can contribute by 
increasing the expression of Fas-L. In contrast, Jnk null MEFs did exhibit a defective 
apoptotic response to stress- induced stimuli, including UV radiation, the DNA 
Genes Summary of phenotypes 
ERK 1/2 
Decreased T cell responses in thymus 
Lack of mesoderm differentiation 
Defects in the placenta 
JNK 
Defects in T cell activation and apoptosis of thymocytes 
Less susceptibility to insulin resistance in diabetes models 
Defects in neural tube closure 
Increased IL-2 production in T cells 
Resistance to UV-induced apoptosis in embryonic fibroblasts 
p38 
Defects in placental angiogenesis 
Defects in Epo production 
Angiogenic defects in the placenta and peripheral vessels 
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alkylating agent methyl methansulfonate and the translational inhibitor anisomycin. The 
defect in apoptosis correlated with failure to induce mitochondrial depolarization, 
cytochrome c release and subsequent caspase activation [86]. Translocation of JNK to 
mitochondria has been reported in response to DNA damage supporting the 
involvement of mitochondria in JNK-mediated apoptosis [95]. The Bcl-2 proteins are 
potential targets of JNK involved in regulation of cytochrome c release [80]. 
Phosphorylation of Bcl-2 and Bcl-xL by JNK has been shown in vitro and is suggested 
to abrogate their anti-apoptotic functions [96,97]. JNK is also reported to phosphorylate 
the pro-apoptotic protein Bad resulting in abrogation of its pro-apoptotic function 
(Donovan et al., 2002). Although involvement of JNK in pro-apoptotic signaling is 
generally accepted, apoptosis does not represent the only possible outcome of JNK 
activation, since most forms of stress do not cause apoptosis under conditions that are 
sufficient for JNK activation [80]. This may be due to parallel activation of survival-
mediating pathways such as ERK, Akt/PKB, NF-B that can block pro-apoptotic 
signaling [91].  Increasing evidence in the literature suggests that the duration of JNK 
activation is important for the outcome, i.e., sustained JNK activation is associated with 
apoptosis, whereas transient activation primarily mediates pro-survival signaling [98].  
Similar to JNK pathways, the involvement of p38 MAP kinase in apoptosis is also 
diverse. It has been shown that p38 signaling promotes cell death [99,100], whereas it 
has also been shown that p38-MAPK cascades enhance survival and cell growth 
[101,102].  Specific p38-MAPK inhibitor SB203580 blocks anti-CD3 mAb-induced T 
cell apoptosis [103]. MKK3 and MKK6 may therefore induce pro-apoptotic signals 
through the activation of p38 kinases and induce apoptosis. Inactivation of p38 results in 
embryonic lethality around embryonic day 11 [104]. In line with this finding, it has been 
shown that activation of p38  by exposure to UV leads to G2/M cell cycle arrest by 
suppressing CDC2 via the phosphatase CDC25 [105]. CDC2 can induce the 
phosphorylation of the BH3-only protein BAD and thus triggers neuronal apoptosis 
[69]. In conclusion, similar to the JNK pathways, p38 MAP kinase signaling plays 
multiple roles in cells such as differentiation, proliferation, cytokine secretion, as well 
as cell death. 
 
ERK 1/2 are activated by various growth factors and induce transition from the 
quiescent state into the cell cycle. ERK signaling pathways are also involved in cell 
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proliferation, differentiation, actin cytoskeleton reorganization, and cell migration. 
Moreover, ERKs are also involved in the stress response and cell death [10,80,88]. It 
has been shown that irradiation stresses lead to phosphorylation of the epidermal growth 
factor receptor (EGFR) in cancer cell lines, which is mediated by radiation-induced free 
radicals and results in activation of ERKs [106]. Similarly, UV irradiation induces the 
activation of ERK in a number of cell types, and the UV-induced ERK activation 
involves the activation of EGFR [10,80].  
 
The differential contribution of different MAP kinase family members to 
apoptosis has been examined after withdrawal of NGF from rat PC-12 
pheochromocytoma cells [91]. NGF withdrawal resulted in sustained activation of the 
JNK and p38-MAP kinases and inhibition of ERK 1/2. The effects of dominant-
negative or constitutively activate forms of JNK, p38, and ERK 1/2 signaling pathways 
demonstrated that activation of JNK and p38 and concurrent inhibition of ERK 1/2 are 
critical for induction of apoptosis in these cells. These results suggest that ERK is a 
survival factor, and JNK and p38 kinases exert opposing effects on apoptosis in this 
experimental cell system [91]. ERK 1-/- mice are viable, fertile, and appear normal. 
However, mice that lack the upstream ERK activator MEK1 die at embryonic day 10.5 
exhibiting defective placental vascularization [107]. The molecular frameworks by 
which ERK, JNK, and p38-MAPK signaling cascades cooperate, concert control of cell 
fates by other signaling, and networks in different cell types must be the focus of future 
studies. 
 
2.1.4.3 AP-1 signaling and apoptosis regulation 
 
AP-1 is one of the first mammalian transcription factors to be identified, but its 
physiological functions are still being unclarified. A wide range of physiological stimuli 
and environmental insults induces AP-1 activity. In turn, AP-1 regulates a wide range of 
cellular processes, including cell proliferation, death, survival and differentiation. The 
main checkpoints of AP-1 signaling have been summarized in Figure 2.5. However, 
despite increasing knowledge regarding the physiological functions of AP-1, the target-
genes mediating cell proliferation and survival functions are not always obvious. AP-1 
is composed of dimeric basic region-leucine zipper (bZIP) proteins that belong to the 
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Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1 and Fra2), Maf (c-Maf, MafB, MafA, 
MafG/F/K and Nrl) and ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) sub-families, 
which recognize either TPA response elements (5[-TGAG/CTCA-3[) or cAMP response 
elements (CRE, 5[-TGACGTCA-3[) [81]. c-Jun is the most potent transcriptional 
activator in its group, whose transcriptional activity is attenuated and sometimes 
antagonized by JunB. The Fos proteins, which cannot homodimerize, form stable 
heterodimers with Jun proteins and thereby enhance their DNA binding activity. 
Regulation of AP-1 occurs through: first, changes in jun and fos gene transcription and 
mRNA level; second, c-Jun and c-Fos protein turnover; third, post-translational 
modifications of c-Jun and c-Fos proteins that modulate their transactivation potential; 
fourth, interactions with other transcription factors that can either synergize or interfere 
with AP-1 activity. Growth factors, cytokines, neurotransmitters, polypeptide hormones, 
cell–matrix interactions, bacterial and viral infections, and a variety of physical and 
chemical stresses induce AP-1 activity [81]. These stimuli activate mitogen activated 
protein kinase cascades that enhance AP-1 activity through the phosphorylation of 
distinct substrates [108]. Serum and growth factors that potently induce AP-1 do so by 
activating the extracellular-signal-regulated kinase subgroup of MAP kinases, whose 
members translocate to the nucleus to phosphorylate, and thereby potentiate, the 
transcriptional activity of ternary complex factors (TCFs) that bind to fos promoters 
[108]. Moreover, the ERKs directly phosphorylate Fra1 and Fra2 in response to serum 
stimulation, possibly enhancing their DNA binding in conjunction with c-Jun. JNK and 
p38 MAP kinase pathways mostly mediate the induction of AP-1 by proinflammatory 
cytokines and genotoxic stress [108,109]. Once activated, the JNKs translocate to the 
nucleus, where they phosphorylate c-Jun and thereby enhance its transcriptional 
activity. The JNKs also phosphorylate and potentiate the activity of ATF2, which 
heterodimerizes with c-Jun to bind divergent AP-1 sites in the c-jun promoter [110]. 
Importantly, the induction of c-Jun expression by certain genotoxic stresses, such as 
short-wavelength ultraviolet (UV) radiation, is much more robust and persistent than the 
induction seen after mitogenic stimulation [81]. Constitutive expression of activated 
oncogenes, such as Ras, also results in an elevation of AP-1 activity, mostly through 
persistent activation of ERK and JNK [111]. The contribution of p38 to AP-1 induction 
could be mediated by the direct phosphorylation and activation of ATF2 [112]. 
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Inhibition of fos and jun expression in mouse fibroblasts using antisense-RNA 
demonstrated their requirement for proliferation and cell cycle progression [113]. 
Furthermore, microinjection of antibodies against c-Fos and c-Jun inhibits serum-
stimulated quiescent mouse fibroblasts from re-entering the cell cycle [114]. Studies 
using fibroblasts derived from fos and jun knockout mice provide partial genetic support 
for these conclusions. Fibroblasts deficient in c-Fos or FosB alone proliferate normally, 
and only cells lacking both proteins have a reduced proliferative capacity [115]. 
Interestingly, c-fos]/] fosB]/] double-knockout mice, but not single knockouts, are 
smaller than their wild type counterparts [115]. Comparing the different AP-1 
deficiency phenotypes, mouse embryo fibroblasts from c-jun]/] embryos exert the most 
severe proliferation defects [116]. These c-jun]/] cells could be passaged in cell culture 
only once or twice before entering a premature senescence. JNK-mediated 
phosphorylation of c-Jun specifically induces cell proliferation, as c-jun (Ala63/73) 
fibroblasts have a proliferation defect, which is less severe than that of c-jun]/]
fibroblasts [117].  
 
The first clues for apoptotic function for AP-1 raised from observations linking 
the induction of c-Fos and c-Jun to conditions that result in cell death. c-Fos is 
continuously induced in the brains of mice treated with kainic acid, which is a potent 
activator of glutamate receptors that induces apoptosis of hippocampal neurons [118]. 
The induction of apoptosis in neuronal and lymphoid cell cultures through withdrawal 
of growth factors is preceded by the induction of AP-1 proteins [119,120]. Nevertheless, 
these findings do not necessarily demonstrate whether c-Jun or c-Fos induction is 
functionally involved in triggering apoptosis. The research efforts demonstrating the 
pro-apoptotic functions of c-Jun and c-Fos was derived from transient overexpression 
experiments, in which c-Jun or c-Fos were found to induce apoptosis in various cell 
lines. The protein expression levels achieved in overexpression experiments are 
extremely high.  Therefore, overexpression experiments could result in aberrant 
physiological function of the overexpressed protein. The anti-apoptotic activity of 
dominant negative c-Jun has been shown to depend, at least partially, on its ability to 
induce the expression of Bim, a proapoptotic Bcl-2 family member [121]. It was not 
clairifed that whether Bim transcription is directly regulated by c-Jun. Fas-ligand (FasL) 
is another important AP-1 target gene. c-Jun-dependent FasL induction was shown in 
several experimental models [81]. However, it should be underlined that the regulation 
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of FasL transcription is not promoted by c-Jun-dependent transcriptional activity. JNK-
mediated phosphorylation has been shown to be involved in c-Jun-induced apoptosis in 
neuronal cells [122]. Expression of c-Jun mutated in the JNK phosphorylation sites has 
been shown to block apoptosis induced by NGF withdrawal. Furthermore, targeting 
JNK3, which is a JNK isoform specifically expressed in neuronal cells, has been 
demonstrated to reduce both AP-1 activation and kainate-induced apoptosis [123]. The 
exact function of AP-1 in cellular responses to genotoxic stress has not been entirely 
identified. The involvement of c-Jun in the induction of UV-induced apoptosis has been 
suggested by several studies [81].  The results have indicated that c-Jun deficient 
fibroblasts and jnk1]/]jnk2]/] double knockout MEFs are less sensitive to UV-induced 
apoptosis [124]. In addition, dominant negative c-Jun reduces apoptosis in human 
monoblastic leukaemia cells exposed to genotoxic insults [125]. In contrast, there are 
other studies, which suggest that c-Jun protects cells against UV-induced cell death 
[126]. This protective activity of c-Jun has been proposed to be mediated through 
activation of STAT3 signaling pathway and inhibition of Fas expression.  
 
Figure 2.5 AP-1 signaling (adapted from [81]). 
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The balance between the pro-apoptotic and anti-apoptotic target genes determine 
whether the outcome will be cell survival or cell death. This balance may vary from one 
cell type to another, and may be dependent on the type and duration of stimulus used to 
activate AP-1, as well as on the activation of other transcription factors. AP-1 acts as a 
molecular switch that retains cells in a certain proliferative steady state or that activates 
apoptotic pathways in response to cellular damage. 
2.1.5 4-Hydroxynonenal 
 
2.1.5.1 Lipid peroxidation and cell signaling 
 
Oxidative stress is recognized as a major upstream “key player” in the signaling 
cascades involved in many critical cellular functions, such as cell proliferation and 
apoptosis, inflammatory responses, cellular adhesion and chemotaxis. An increased 
amount of evidence suggests that many of the effects of cellular dysfunction under 
oxidative stress are mediated by products of non-enzymatic reactions, such as the 
peroxidative degradation of polyunsaturated fatty acids [1,2]. Lipid peroxidation is 
initiated and proceeds by a free radical chain reaction mechanism and lipid 
hydroperoxides are produced as reaction products. Moreover, the decomposition of lipid 
hydroperoxides leads to the formation of a number of breakdown products that display a 
wide variety of damaging actions. Aldehydic molecules generated during lipid 
peroxidation have been implicated as causative agents in cytotoxic and genotoxic 
processes initiated by the exposure of biological systems to oxidizing agents [2]. 
Compared to free radicals, the aldehydes are relatively stable and can diffuse within or 
even escape from the cell and attack targets far from the site of the original event. 
 
Oxidative modifications of lipoproteins, which are either components of cellular 
membranes or circulating in blood, exert many considerable consequences in disease 
pathogenesis. These lipid peroxidation end-products, specifically ox-LDLs, play key 
roles in the evolutionary and progressive pathogenesis of atherosclerosis through 
activation of pro-inflammatory and pro-atherosclerotic signaling pathways [127]. The 
biological responses triggered by ox-LDLs have been shown to be associated with 
various signaling pathways including phospholipases, kinases, transcription factors, 
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calcium and proteases [2,127]. The ox-LDLs may act as ligands and trigger a chain of 
signaling events, which include calcium, cAMP and inositol phosphate pathway. Ox-
LDLs have been shown to increase the cytosolic calcium levels of vascular endothelial 
and smooth muscle cells (SMCs) prior to cAMP activation [128]. It has been 
demonstrated that ox-LDL treatment of SMCs induces an increase in phospholipase C-
mediated phosphoinositide turnover, which depends on receptor signaling and 
internalization of ox-LDLs [128].  In addition to membrane-related signaling events, 
cytosolic targets of ox-LDLS such as PKC family of kinases have been determined 
[129]. Recent studies have also shown that ox-LDLs directly induce tyrosine 
phosphorylation and activation of epithelial growth factor receptor (EGFR), which 
could be also initiated by HNE [130]. Furthermore, ox-LDLs have been shown to 
activate phosphatidylinositol-3-kinase (PI3-kinase) in a macrophage cell line and to 
induce a mitogenic effect via this signaling cascade [131]. Ox-LDLs activate STAT1, 
STAT3 (Signal transducer and activator of transcription) and MAP kinase pathways in 
SMCs and macrophages [132,133].  
 
Gene expression regulation (such as vascular adhesion molecules  
ICAM and VCAM) and modulation of vascular signal transduction participate in 
development and progress of atherosclerotic lesion [127]. Ox-LDLs regulate the 
expression of genes through activation of nuclear transcription factors and their 
upstream activator/inhibitor kinases. Ox-LDLs have been shown to activate AP-1 and 
NF-B DNA binding in endothelial cells, fibroblasts and SMCs [127,134]. PPAR
(peroxisome proliferator-activated receptor ) , which is ligand-dependent nuclear 
transcription factor in macrophage cell lineage, has been shown to be modulated by ox-
LDLs [135]. This event partly explains how lipid peroxidation induces a 
proinflammatory state in tissue microenvironment. All these data demonstrate how lipid 
peroxidation may influence pathophysiological progress not only by exerting direct 
cytotoxic effects but also through modulation of cellular signaling cascades.  
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Figure 2.6 Structure of HNE. 
 
2.1.5.2 Basic Chemistry of 4-Hydroxynonenal 
 
HNE was initially identified and characterized by Hermann Esterbauer’s group 
[136]. HNE is a degradation product of hydroperoxides of n-6 polyunsaturated fatty 
acids such as linoleic acid, linolenic acid and arachidonic acid (Figure 2.6). Physical and 
chemical properties of HNE are summarized in Table 2.2. Studies with hydroperoxides 
of linoleic acid have demonstrated that 9(S)-hydroperoxy-octadecadienoic acid (9(S)-
HPODE) may decompose into HNE through a three-step reaction [137]. 9(S)-HPODE 
cleaves into nonenal and 9-oxo-nonaic acid and peroxidation of nonenal in the position 
4 results in hydroperoxynonenal (HPNE). The hydroperoxy group of HPNE can then be 
reduced to form HNE.  
 
Table 2.2 Some physical and chemical properties of HNE 
• Molecular formula: C9H16O2
• Molecular weight: 156.22  
• FW: 156.2  
• colorless liquid  
• soluble in most organic solvents, e.g. alcohols, hexane, chloroform  
• slightly soluble in water (6.6 g/L = 42 mM)  
• UV maximum 
223nm, e 13750 (water) 
221nm, e 13100 (ethanol) 
215nm, e 14400 (hexane) 
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The basic chemical structure of HNE can be defined as a trifunctional molecule: a 
hydroxyl group, C=C double bond and a carbonyl group, all contribute to the high 
reactivity of HNE. HNE mainly reacts with thiol and amino groups, primarily with 
cysteine, histidine and lysine residues through formation of Michael adducts to the C=C 
bond (Figure 2.7).  
 
Figure 2.7 Michael addition of thiols.  
 
C2-C3 bond becomes more flexible and further reactions involving the carbonyl and the 
hydroxyl group may occur. Primary amines may react with the carbonyl group and form 
Schiff bases (Figure 2.8). 
Figure 2.8 Schiff base formation by HNE.  
There are also oxidation/reduction of carbonyl group and the epoxidation of the 
C=C double bond among the possible chemical reactions of HNE. When we consider 
the chemical structure of HNE, it is clear that the lipophilic properties are more 
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important than its hydrophilic properties and HNE have a tendency to concentrate in 
various biomembranes. HNE is also genotoxic at micromolar concentrations, which is 
exhibited by elevated chromosomal aberrations and formation of micronuclei [138]. The 
most common way for the formation of HNE-adduct is direct interaction with guanosine 
moieties of DNA, which are also observed in human and rodent genomes [138]. HNE 
treatment also results in the inhibition of DNA, mRNA and protein synthesis in various 
cell lines [139].  
 
2.1.5.3 Cellular Metabolism of HNE 
 
Lipid peroxidation is combined with the formation of reactive aldehydes in most 
of the cases; HNE is one of the most important of these aldehydes. HNE undergoes 
several reactions with cellular macromolecules (proteins, peptides, phospholipids, 
nucleic acids) and   mammalian cells have many active pathways of HNE metabolism. 
The metabolic pathways of HNE have been investigated in various mammalian cells 
and organs, such as endothelial cells, fibroblasts, tumor cells and heart [140]. The 
physiological blood serum level of HNE was determined as 0.1-10 µM and HNE 
concentrations have been significantly elevated in tissues under oxidative stress 
[141,142]. Thereby, the organism utilizes highly effective mechanisms to prevent the 
accumulation of this highly reactive substance. HNE is mainly removed by its 
intracellular metabolism. In rat hepatocytes at pH 7.4 and 37 °C, nearly 95% of 100 µM
HNE was shown to degrade within 3 min of incubation, presumably due to higher 
metabolism by glutathione-dependent enzymatic meachanisms (Figure 2.9) [140]. The 
degradation of HNE was also shown to be dependent on the cell concentration and 
initial HNE concentration. The main biochemical reactions of HNE has been 
demonstrated to lead to the formation of alcohol 1,4-dihydroxynonene, 4-
hydroxynonenoic acid, and conjugated products such as aldehyde-glutathione conjugate. 
The corresponding HNE-metabolizing enzymes catalyze these reactions: alcohol 
dehydrogenases (NADPH-dependent reduction of the carbonyl group), aldehyde 
dehydrogenases (NAD+-dependent oxidation of the carbonyl group) and glutathione S-
transferases (Michael addition of thiols). Glutathione S-transferases (GST) and aldeyhde 
dehydrogenases are present in almost all mammalian cell types. GST activity is much 
faster than non-enzymatic Michael addition reaction.  
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Figure 2.9 The typical degradation profile of HNE in mammalian cells [140].  
 
Increased HNE levels or addition of HNE into the medium results in a rapid 
decrease of intracellular GSH levels and one of the main primary metabolites of HNE is 
the HNE-GSH adducts [143]. After this rapid and transient GSH decrease, synthesis of 
GSH is induced through activation of glutamate cysteine ligase (GCL), which catalyzes 
the initial step in de novo synthesis of GSH. Exposure of rat L2 cells and human HBE1 
cells to HNE causes an increase in GSH biosynthesis, which may be responsible for the 
cellular protection against HNE-induced cytotoxicity [144,145]. An increase in the 
intracellular content of GSH is a result of an effort to balance between loss through use 
and de novo GSH synthesis. This induction could be related to either direct conjugation 
or depletion of GSH or activation of MAP kinases and AP-1. In rat L2 cells, activation 
of ERK 1/2 and JNK pathways has been shown to be involved in HNE-mediated 
signaling for GSH synthesis [144]. In contrast, there are also studies, which could not 
demonstrate the involvement of MAP kinases in GSH synthesis [145]. Thereby, the 
exact mechanism behind the induction of GSH by HNE remains to be identified. 
Furthermore, the total rate of HNE formation and degradation also depends on the ratio 
between oxidative and reductive pathways of the HNE metabolism in different cellular 
conditions and oxygenation/reperfusion. In spite of the rapid response against HNE 
accumulation via cellular metabolic/protective pathways, protein modification by HNE 
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could be detected in many experimental systems. HNE protein binding has been shown 
to be in the range between 1% and 8.5% of total cellular proteins [146]. Many different 
cellular proteins such as Na+-K+-ATPase, PARP, Complex I, MAP kinases and PKCs 
have been shown to be modified by HNE and the result was inhibitory in most of the 
cases [146]. The degradation of oxidized and oxidatively modified proteins is an 
essential component of cellular defense system.  The fate of a HNE-modified protein is 
either degradation by the 20S proteosome pathway or cross-linking and accumulation 
[146]. Both of the pathways may lead to pathophysiological sequences of events, 
leading impairment of cellular and organ dysfunction. Nevertheless, intracellular HNE-
metabolizing/degrading defense systems are critical for protection of proteins and other 
macromolecules from modification by aldehydic lipid peroxidation products.  
 
2.1.5.4 HNE and cellular signaling 
 
The manipulations of cellular signaling pathways by lipid peroxidation have been 
described above. HNE is one of the most abundant aldehydic components of ox-LDL 
and it exerts similar effects on intracellular and extracellular signaling cascades [1,2]. A 
brief synopsis of HNE-modulated signaling pathways is shown in Table 2.3. Here a 
short comprehensive summary of HNE-induced signaling pathways mainly focused on 
cell survival and cell death will be given. Protein kinases C are variously distributed 
protein kinases, which are differentially involved in signal transduction, differentiation 
and apoptosis [147]. Recent data has demonstrated that PKCs are among a group of 
cell-signaling molecules that are modulated by redox modification and functional 
alterations that mediated stress-mediated cellular responses [147]. HNE has been shown 
to activate phospholipase C, which results in an increased production of inositol 
triphosphate (IP3) and diacylglycerol (DAG) as well as protein kinase C activation 
[148]. Interestingly, subtypes of protein kinase C is differentially regulated by HNE.  
HNE treatment has been shown to induce a decrease in PKC activity in a dose-
dependent manner [149]. By contrast, its effect on PKC-I and PKC-II was biphasic 
and dependent on HNE concentration [150]. HNE was also shown to stimulate 
cathepsin D intracellular transport and secretion in isolated rat hepatocytes and 
enhanced production of amyloid- protein in neuronal cells [151]. HNE at similar 
concentrations that activate JNK, also markedly activated novel PKC isoforms, in 
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particular PKC in hepatocytes [152]. Through this effect, HNE has been shown to 
activate AP-1, which could be blocked by a specific novel PKC inhibitor, rottlerin.  
 
Tyrosine kinase receptors (RTK) such as EGFR and PDGFR are also among the 
cellular targets of HNE. In intact living cells, both ox-LDL and HNE has been shown to 
trigger HNE-adduct formation and activation of PDGFR and EGFR [130]. HNE-
PDGFR adducts have also been detected in atherosclerotic lesions, which may be 
involved in SMC migration and proliferation in vascular intimal area and synthesis of 
matrix molecules in the formation of atherosclerotic cap [153]. HNE at 1 µM
concentration induced EGFR and PDGFR autophosphorylation, recruitment of SH2 
domains to phosphorylated receptor and activation of downstream signaling cascades 
such as MAP kinases. HNE has also been reported to induced EGFR signaling and 
receptor clustering along with apoptosis, when used at higher concentrations [154]. 
Moreover, modulation of HNE-induced tyrosine kinase activities at the level of kinase 
level by phenolic compounds has been demonstrated [155]. Mitogen-activated protein 
kinase cascades are pivotal mediators in cell signaling and HNE-induced upstream 
pathways may lead to downstream activation/inhibition of both ERK 1/2 and other two 
stress-activated protein kinases (JNK and p38) [2,3]. HNE may also induce c-Fos or c-
Jun gene expression and consequent activation of AP-1 downstream of MAP kinases. 
HNE has been shown to activate AP-1 in PC12 pheochromacytoma cells through 
activation of JNK without concurrent p38 activation [156]. In rat epithelial cells, HNE 
induced both JNK and p38 activation and in vascular smooth muscle cells HNE has 
been shown to activate all three kinases and c-Fos activation [157].  
 
Regarding another important redox-sensitive transcripition factor, NF-B, HNE 
did not seem to influence its activation and nuclear translocation by when utilized alone 
[158]. In contrast, HNE has also been shown to activate NF-B and to induce apoptosis 
in vascular smooth muscle cells [159]. Interestingly, HNE has been shown to counteract 
the lipopolysaccharide-induced NF-B activation in a macrophage cell lineage via 
inhibiting IKK signalsome pathway [160].  All these data confirm the complex and cell-
dependent integration of signaling pathways activated by HNE.  
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HNE as a signal for biological functions  
 
(I) Enzymatic activities/functions 
 
• Stimulation of chemotaxis  
• Activation of adenyl cyclase  
• Activation of phospholipase C  
• Activation of AP-1 binding  
• Activation of JNK  
• Activation of PKCI and II  
• Stimulation of caspases  
• Inhibition of PDGFR tyrosine kinase  
 
(II) Stimulation of gene expression 
• Heat shock proteins (HSP 70)  
• Procollagen A1  
• Aldose reductase  
• Heme oxygenase  
• TGF1
• c-Glutamyl cysteine synthetase  
• MCP-1  
• -secretase (BACE)  
• TIMP-1  
 
(III) Modulation of proto-oncogenes, cell cycle and proliferation 
 
• Inhibition of c-Myc mRNA  
• Inhibition of c-Myb mRNA  
• Block of cell cycle in G0/G1  
• Stimulation of c-Jun mRNA  
• Stimulation of growth of vascular SMCs 
• Stimulation of cyclins D1and D2  
• Modulation of pRb/E2F pathway  
 
Table 2.3 Cellular signaling pathways regulated by HNE.
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2.1.6 Resveratrol 
 
Phytochemicals are compounds found widespread in plants, which have beneficial 
effects on human health and have potential chemoprevention properties. The main 
families of phytochemicals involve flavonoids, phytoestrogens, isothiocyanates, 
monoterpenes, organosulfur compounds, saponins, capsaicin, and sterols. Recent 
molecular and cellular studies have focused on the beneficial effect of dietary 
phytoestrogens in reducing the risk of cardiovascular diseases, diabetes and cancer. 
Phytoestrogens are polyphenolic non-steroidal molecules acting as functional analogs of 
mammalian estrogen 17--estradiol (E2) and they have potential applications in 
hormone therapy to prevent menopausal syndromes and osteoporosis [161,162]. 
Resveratrol (trans-3,5,40-trihydroxystilbene) has been identified as the major active 
compound of the stilbene phytoestrogens (Figure 2.10) [163]. It exists as trans and cis 
isomers, however only the trans form of resveratrol has been reported to be estrogenic. 
The inverse relationship between risk of ischemic heart disease and French-pattern 
dietary intake, moderate consumption of red wine and consumption of foods high in 
saturated fats raised a wave of interest in monitoring the presence of resveratrol in red 
wine [164]. Resveratrol is found only in skin of grapes, not in grape flesh, making this 
stillbene the active ingredient of red wine but resulting in low levels in white wine 
[164]. The gastrointestinal absorption, distribution and metabolism of resveratrol have 
been evaluated.  The bacterial microflora in the ileum and cecum plays an important 
role in the metabolism and absorption of resveratrol. Kinetics of trans- and cis-
resveratrol (3,4',5-trihydroxystilbene) after oral administration of red wine in rats 
showed that a fraction of resveratrol (6.5 mg/l) was absorbed by rats and can be detected 
in considerable concentrations in plasma [165].  
 
Resveratrol has been shown to protect against reactive oxygen species (ROS). 
Reactive oxygen species such as hydroxyl radical (.OH), superoxide radical (O2.-) and 
hydrogen peroxide (H2O2) are generated as by-products of molecular cellular events and 
involved in initiation of oxidative stress. Antioxidants provide a redox balance and 
protect the cellular structures and macromolecules against ROS-induced damage. 
Nevertheless, when the defense system is deranged due to excess generation of ROS, 
cell injury or even cell death may occur due to oxidative damage to DNA, proteins and 
lipids. 
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Figure 2.10 Structure of resveratrol. 
 
Resveratrol has been shown to inhibit the pro-oxidant effect of tert-butyl 
hydroperoxide by scavenging of radicals in rat embryonic mesencephalic cells [166]. 
Furthermore, resveratrol has been demonstrated to exert an inhibitory effect on LPS-
induced superoxide radical and hydrogen peroxide production by macrophages [167]. 
Regarding the proposed role of ox-LDL in the development of atherosclerosis, studies 
have been utilized to evaluate the role of resveratrol on inhibition of LDL oxidation and 
atherosclerosis. A 45% decrease in plasma LDL concentration, and a 25% reduction in 
plasma cholesterol levels was detected in hyperlipidermic hamsters fed with red wine 
[168]. Resveratrol has been shown to decrease VLDL/LDL and triglyceride levels in 
rats with hypercholesterolemia and hypertriglyceridemia, when orally administrated to 
these animals. Resveratrol has also been shown to inhibit the peroxidation of membrane 
lipids that destroys the phospholipid bilayer of the cellular membrane resulting in 
irreversible cell damage [169]. In human primary cell cultures and rat liver microsomes, 
it has been demonstrated that resveratrol inhibited the lipid peroxidation induced by free 
radical donors [170]. In addition to inhibition of LDL and cell membrane oxidation, 
resveratrol can protect cells against the cytotoxic effect of ROS by increasing their 
resistance [171].  
Resveratrol was shown to exhibit protective effects against H2O2- and -amyloid-
induced oxidative stress and cell death in rat pheochromocytoma cells by increasing the 
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resistance of these cells to oxidative stress and cell death by attenuating intracellular 
ROS accumulation and restoring the levels of some marker proteins of apoptosis such as 
Bax, Bcl-xL, JNK, and PARP [172,173].  Furthermore, resveratrol was also shown to 
inhibit TNF- and LPS-induced activation of NF-B binding and subsequent apoptosis 
in human myeloid cells [174]. The molecular mechanism of NF-B inactivation by 
resveratrol is through inhibition of IKK signalsome and IB- phosphorylation and 
degradation.  
 
Resveratrol is effective in blocking, reversing or retarding the process of 
carcinogenesis [175]. In this context, resveratrol functions as a cancer chemopreventive 
agent, which has been shown to inhibit the ribonucleotide reductase, which is involved 
in the cell proliferation and cell cycle progression [176]. In several human cancer cell 
lines, resveratrol has been demonstrated to induce cell cycle arrest and induced 
apoptosis [175]. The resveratrol-mediated cell death involved increased caspase-activity 
and Bax levels, and decreased Bcl-2 and Bcl-xL levels [177]. The modulation of cellular 
signal transduction pathways by naturally occurring substances such as resveratrol has 
been recognized as a novel therapeutic approach against human diseases 
 
2.1.7 Apoptosis in disease pathogenesis 
 
Over the past decade, our understanding of apoptosis, or programmed cell death, 
has increased greatly, with the identification of some of the major components of the 
apoptotic program and the processes regulating their activation. Although apoptosis is 
an intrinsic process present in all cells, it can be regulated by extrinsic factors, including 
growth factors, cell surface receptors, cellular stress and hormones. In a simplified 
vision, the diseases in which apoptosis has been involved can be divided into two 
groups: those in which there is an increase in cell survival (or diseases associated to 
inhibition of apoptosis), and those in which there is an increase in cell death (diseases 
associated to increased apoptosis).  
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2.1.7.1 Diseases associated with inhibition of apoptosis 
 
This group of diseases includes those diseases in which an excessive accumulation 
of cells occurs due to increased cell proliferation. Recently, it has been demonstrated 
that defective apoptosis is also a major part of excessive accumulation of cells. The role 
of apoptosis in some of these diseases will be described in this section (Table 2.4).  
2.1.7.1.1 Cancer 
 
In both solid and hematological tumors, it has been demonstrated that the 
malignant cells display an abnormal response to the induction of apoptosis. It has been 
demonstrated that in neoplasias, cell cycle regulator genes/oncogenes such as p53, ras 
or c-myc suffer mutations, inactivation or deregulations associated to malignant 
transformation; these genes also regulate apoptosis in those cells [178]. Further genes, 
such as bcl-2, also overexpressed in tumour cells, and the expression of bcl-2 is 
currently considered a predictive factor for worse prognosis in prostate, breast and colon 
cancer and in neuroblastomas [179,180]. Further to the studies that reveal a correlation 
between apoptosis inhibition and malignant transformation, it has been also shown that 
resistance to apoptosis in tumor cells also contributes to chemotherapy resistance and 
tumor escape mechanisms [181]. 
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Table 2.4 Diseases related to apoptosis 
 
2.1.7.1.2 Autoimmune diseases 
 
The apoptotic death of clones of auto-reactive lymphocytes or of lymphocytes, 
which are not effective in the immune response, has been shown to be fundamental in 
the development of the immune system. Furthermore, it has been demonstrated that 
autoimmune diseases, such as systemic lupus erythematosus, are associated to mutations 
in genes rendering the lymphocytes resistant to apoptosis [182]. Normal thyrocytes 
could induce apoptosis of infiltrating activated T cells and protect against T cell-
mediated apoptosis. In Hashimoto's thyroiditis (HT), Fas-mediated apoptosis of thyroid 
cells due to at least two distinct mechanisms, the first by infiltrating activated T cells, 
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and the other by FasL-positive thyroid cells in a suicidal fashion [183]. A common 
feature of autoimmune diseases such as systemic lupus erythematosus (SLE) is the 
breakdown of tolerance of self-antigens, a consequence of which is the production of 
autoantibodies reactive with multiple self-proteins [182]. Evidence is accumulating that 
modifications of autoantigens during apoptosis lead to the development of 
autoantibodies by bypassing the normal mechanisms of tolerance. Tissue homeostasis is 
maintained through a balance between cell proliferation and apoptotic cell death. 
Rheumatoid arthritis (RA) is characterized by pronounced hyperplasia of the synovial 
tissue, cell infiltration and periarticular osteoporosis. Enhanced Bcl-2 expression and 
NF-B nuclear translocation of synovial cells are induced by inflammatory cytokines 
[184]. These synovial cells become resistant toward apoptosis triggered by various 
stimuli. The infiltrated cells, which are defective in activation-induced cell death, can 
cause autoimmunity by allowing the survival of autoreactive T and B cells [184]. These 
data suggest that apoptosis might be implicated with the pathogenesis of autoimmunity, 
whereas the mechanisms might be distinct in each autoimmune disease 
 
2.1.7.2 Diseases associated with increased apoptosis 
 
Increased cellular apoptosis has also been implicated in the pathogenesis of a 
number of diseases, which are characterized by excessive cellular damage and loss of 
physiological homeostasis. 
 
2.1.7.2.1 Neurodegenerative diseases 
 
Neurodegenerative diseases are characterized by extensive apoptosis of the 
neurons [185]. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis 
and retinitis pigmentosa are among the most common neurodegenerative disorders. 
Increased neurological susceptibility to apoptosis neuronal cells in Alzheimer’s disease 
has been shown to be related to oxidative stress, mitochondrial insults and neurotoxins 
[186]. 
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2.1.7.2.2 Hematological disorders 
 
Mature blood cells are derived from hematopoietic precursors located in the bone 
marrow. Haematopoiesis, and hence the presence of mature cell forms, is regulated by a 
number of hematotrophic factors (erythropoietin, colony stimulating factors, cytokines). 
Hematological turnover is a dynamic process in which the number of mature forms in 
peripheral blood regulates the generation of new cells. The presence of altered trophic 
factors, or of abnormal levels of normal hematotrophic factors, would favour the 
accumulation of immature cell forms, which would not be effectively regulated in the 
peripheral blood and excessive apoptosis [187]. 
 
2.1.7.2.3 Ischemia-reperfusion 
In myocardial infarction, ischemic renal damage or cerebrovascular events, the 
cells in and around ischemic zone are lost through apoptosis. Alterations in the 
biochemical metabolism and pro-apoptotic signaling pathways accompany the ischemic 
process. However, in these diseases oxygenation/reperfusion also induces further 
apoptosis, as it is associated to a sudden increase in reactive oxygen radicals that could 
also induce apoptosis in these cells [188]. 
 
2.1.7.2.4 AIDS 
 
The CD4+ cells of the HIV (+) patients die through apoptosis when stimulated in 
vitro. Moreover, HIV infection of cells from healthy subjects induces apoptosis of 
CD4+ cells [189]. However, further to this, not only the infected cells but also non-
infected cells undergo apoptosis. There is a large number of studies demonstrating that 
cell apoptosis plays a relevant role in the etiology of many diseases, and that a wide 
range of pharmacologic agents (cytotoxic agents, hormones, anti-inflammatory drugs) 
are effective through inducing apoptosis of target cells. Nevertheless, it appears to be 
evident that the future of such studies should be aimed both at documenting new 
associations between apoptosis and disease and at developing new therapies based on 
the modulation of apoptosis.  
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2.1.7.2.5 Atherosclerosis 
 
Atherosclerosis and its complications such as acute myocardial infarction and 
stroke are the leading cause of mortality and morbidity in industrialized and developing 
countries. The pathophysiology of atherosclerosis is characterized by an initial fatty 
streak formation, which progresses by alteration of endothelial function, expression of 
adhesion molecules, inflammatory response as well as lipid retention/oxidation and 
engulfment by macrophages, which forms one of the most characteristic hallmarks of 
atherosclerosis: foam cells [127]. The cell proliferation, apoptosis and migration 
contribute to the progression of atherosclerotic lesion. The proliferation and intimal 
migration of vascular smooth muscle cells results in increased synthesis of collagen and 
formation of fibrous plaques around lipid cores, which are mainly formed by lipid-laden 
macrophages. In advanced lesions, the central parts of these lipid cores become highly 
instable because of the necrosis and apoptosis of cellular structures of the lipid core 
[127]. The rupture of the fibrous plaque occurs usually at the shoulder region of the 
lesion, which is followed mostly by formation of a thrombus and increased risk of acute 
coronary syndromes and stroke. The progression of an atherosclerotic lesion is 
evolutionary and chaotic, but we can describe the pattern of lesion development into 
two main phases with overlapping characteristics. The first phase is defined by 
endothelial dysfunction and inflammation with prominent lipid retention but minimal 
lipid peroxidation. This pro-inflammatory microenvironment predominantly provokes a 
proliferative response for vascular smooth muscle cells, which is followed by intimal 
migration and neointima formation. It has been also speculated that endothelial cell 
apoptosis has a role in development of endothelial cell dysfunction and atherosclerotic 
lesion areas show extensive endothelial cell turn-over with dysfunctional endothelial 
cells. [190]. Thereby, functional involvement of apoptosis in the first phase of lesion 
development targets two cell types:  a preferential pro-apoptotic stimulation for 
endothelial cells and an anti-apoptotic and proliferative stimulation for smooth muscle 
cells. The second phase of lesion progression involves increased inflammatory response 
and lipid retention/peroxidation, which trigger the formation of oxidized low density 
lipoprotein (ox-LDL) particles in the vascular wall, alteration of redox balance and 
modification of cellular proteins, DNA and lipids [191]. This leads to plaque 
development and stabilization of the plaque by extracellular matrix and cellular support 
formed by vascular smooth muscle cells.  In more advanced lesions extensive apoptosis 
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of cells, which form the plaque (lipid-laden macrophages and SMCs), may lead to 
thinning of fibrous support, plaque destabilization, rupture and thrombosis, which may 
result in clinical presentation of the lesion such as acute myocardial infarction 
[192,193].  
 
In this study, our aim was to identify the HNE-induced apoptosis signaling 
pathways in 3T3 fibroblasts and the molecular signaling targets of resveratrol in these 
signaling cascades. The fact that that apoptosis is a major cellular event in disease 
pathogenesis underlines the importance of understanding signaling pathways in 
apoptotic machinery and development of small molecule approach targeting these 
signaling cascades. 
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CHAPTER 3 
 
3 MATERIALS AND METHODS 
 
3.1 Materials 
 
All chemicals and growth mediums used in this study were purchased from 
SIGMA (Darmstadt, Germany) otherwise indicated.  
3.1.1 Chemicals and antibodies 
 Chemicals and antibodies that are used are listed in Appendix A. 
3.1.2 Molecular biology kits 
 Molecular biology kits that are used for DNA isolation, caspase activation, 
apoptosis screening, gene transfection, plasmid isolation and protein analysis are listed 
in Appendix B. Other specialty materials including DNA and protein markers are 
indicated in Appendix C. 
3.1.3 Equipment 
 Equipment that is used for general laboratory procedures are listed in Appendix D. 
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3.1.4 Radioactivity 
 Radioactivity has been used under international radioprotection regulations. 
Adenosine 5’-[-32P] triphosphate with a specific activity of 3000 Ci/mmol was 
obtained from Izotop (Hungary). 
3.1.5 Buffers and solutions 
 Standard buffers and solutions used in cloning and molecular manipulations were 
prepared according to the protocols in Cell Proliferation and Apoptosis, Mehmet et al, 
2004 and Molecular Cloning: A Laboratory Manual, Sambrook et al., 2001.  
3.1.6 Buffer for agarose gel electrophoresis 
 1 X TAE (Tris-EDTA-Acetate) buffer was used for preparation of 1% and 1.5% 
agarose gels. Gels were run at 100mV for 45 minutes. DNA was visualized by including 
0.005% ethidium bromide in the gel during its preparation. 
3.1.7 Buffer for SDS polyacrylamide gel electrophoresis 
 1X Tris-Glycine-SDS (sodium dodecyl sulfate) buffer was used for 
polyacrylamide gel electrophoresis. Gels were run at constant voltage, 60 mV, for about 
2 hours. 
3.1.8 Oligos and plasmids 
AP-1 TRE consensus oligonucleotides were obtained from Promega, Madison, 
WI, USA. The oligonucleotide sequences are as follows; 5´-CGC TTG ATG AGT CAG 
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CCG GAA-3´ and 3´-GCG AAC TAC TCA GTC GGC CTT-5´. The maps of pcDNA3 
and pcDNA1 vectors are given in Appendix C. 
3.1.9 Buffers for Western Blotting 
 Transfer buffer (Tris base, Glycine and methanol) was used for blotting the the 
proteins into PVDF membrane. The membranes were blocked with blocking solution, 
5% milk powder in PBS-Tween 20 (0,25%) and washed with washing buffer, PBS-
Tween 20 (0,25%). The antibodies were diluted in 10% milk diluent, 10% PBS-Tween 
20 (0,25%) and 80% sterile distilled water.  
3.2 Methods 
All methods used in this study are explained below; 
3.2.1 Cell Culture                  
Swiss 3T3 fibroblasts were cultured in DMEM supplemented with 10% heat-
inactivated FBS, 2 mM Glutamine, 100 IU/ml penicillin and streptomycin. Cultures 
were maintained in 37°C in a humidified 5% CO2 atmosphere. Cells were seeded in 6-
well culture plates (1 x 106 cells/well), 60 mm culture flasks (1x 107 cells/well) or 96-
well plates (1 x 104 cells/well) and treated as indicated in the experimental protocols. 
Ethanol d 0.05%, v/v) was added to all control wells in each experiment. For 
cryopreservation, cells were trypsinized and resuspended in complete medium 
containing 10% heat-inactivated FBS and 10% DMSO (freezing medium). The cell 
suspension in freezing medium transferred into cryovials, frozen at -70 º C for 24 hours, 
and then stored in liquid nitrogen to remain until thawing.  
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3.2.2 Protein isolation 
3.2.2.1 Total protein isolation 
Treated and control 3T3 fibroblasts were harvested, washed with ice-cold 
phosphate buffered saline and lysed on ice in a solution containing 20 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, Nonidet P-40 0.5%, (v/v), 1 mM EDTA, 0.5 mM PMSF, 1 
mM DTT, protease inhibitor cocktail (Complete from Roche, Mannheim, Germany) and 
phosphatase inhibitors (Phosphatase inhibitor cocktail 1 and 2, Sigma, Darmstadt, 
Germany). After cell lysis, cell debris was removed by centrifugation 15 min at 13000g
and protein concentrations were determined with Bradford protein assay. 
 
3.2.2.2 Nuclear and cytoplasmic protein isolation 
 
Nuclear and cytoplasmic proteins were isolated as described before with minor 
modifications [194]. Briefly, cells were treated as indicated and washed with ice-cold 
PBS, then scraped and harvested by centrifugation. They were resuspended in 1 ml of 
cold PBS and transferred to 1.5-ml Microfuge tubes. After centrifugation at 300g for 30 
s, cells were lysed by incubation for 10 min in 200 µl of cold hypotonic buffer [10 mM 
Hepes/KOH, (pH 7.9), 10 mM KCl, 2mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol 
(DTT), 0.5 mM PMSF, protease inhibitors and Nonidet P-40 (0.2%)]. After 
centrifugation at 13000g for 30 s, supernatants containing cytoplasmic proteins were 
removed and stored at -70°C. The nuclear pellet was washed and nuclear protein 
isolation was carried out by incubation for 20 min on ice in a cold saline buffer [20 mM 
Hepes/KOH (pH 7.9), 1.5 mM MgCl2, 0,2 mM EDTA, 650 mM NaCl, glycerol (25%, 
v/v), 1 mM DTT, 0.5 mM PMSF and protease inhibitors. After centrifugation at 13000g
for 20 min at +4°C, supernatants containing nuclear proteins were removed and stored 
at -70°C. Protein concentrations were determined by Bradford reagent (Bio-Rad, 
Munich, Germany). 
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3.2.2.3 Mitochondrial protein subfractionation 
 
3T3 fibroblasts cells were seeded in 6-well plates (1x 106 cells/well) and after 
indicated treatments, cells were harvested, washed once with phosphate-buffered saline 
(PBS) and lysed for 30 s in 100 µl ice-cold lysis buffer [250 mM sucrose, 1 mM EDTA, 
0.05% digitonin, 25 mM Tris, pH 6.8, 1 mM dithiothreitol (DTT), 0.1 mM PMSF and 
protease inhibitor cocktail (CompleteMini, Roche, Germany)]. Cell lysates were 
centrifuged at 13000g at +4ºC for 5 min and supernatants (mitochondria-free cytosolic 
extracts) and the pellets (mitochondrial fraction) were separately obtained. 
 
3.2.3 Electromobility Shift Assay (EMSA) 
 
The gel shift method was performed as described before [194]. Briefly, the 
oligonucleotide probe was labeled with -32P-dATP (3000 Ci/mmol) using T4 
polynucleotide kinase and then labeled oligonucleotide was purified on a Sephadex G-
25 column. Five µg of nuclear proteins were incubated for 20 min at room temperature 
with 0.2 ng of 32P-labelled oligonucleotide probe in gel shift binding buffer 1.25 µg of 
BSA and 1.25 µg of poly (dI-dC).poly (dI-dC) in 20 mM Hepes/KOH, 75 mM NaCl, 1 
mM EDTA, 5% (v/v) glycerol, 0.5 mM MgCl2, 1 mM DTT (pH 7.9) (final volume 10 
µl). DNA-protein complexes then resolved on a non-denaturating 6% polyacrylamide 
gel run for 3 h at 180 V. The gel was then dried and autoradiographed on Kodak X-ray 
film. 
The consensus sequences of the oligonucleotides used in this work were 5’-
CGCTTGATGAGTCAGCCGGAA-3’ and 3’-GCGAACTACTCAGTCGGCCTT-5’. 
For competition experiments unlabelled probe was added in excess (50x) in the binding 
buffer and for supershift experiment incubation with anti-c-Jun and anti-c-Fos 
antibodies was performed before addition of 32P-labelled oligonucleotide probe into the 
binding buffer. 
 
3.2.4 Immunoblots 
 
Proteins (40 µg) were separated on a 10-15% SDS-PAGE and blotted onto PVDF 
membranes. The membranes were then blocked with 5% dried milk in PBS-Tween20 
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and incubated with appropriate primary and horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Amersham Pharmacia Biotech, Freiburg, Germany) in antibody 
buffer containing 10% (v/v) Milk Diluent/Blocking concentrate. After required washes 
with PBS-Tween 20, proteins were finally analyzed using an enhanced 
chemiluminescence detection system (ECL-Plus, Amersham Pharmacia Biotech, 
Freiburg, Germany) and exposed to Hyperfilm-ECL (Amersham Pharmacia Biotech, 
Freiburg, Germany). 
 
3.2.5 Apoptosis and cell death  
 
3.2.5.1 MTT assay 
 
Cell death was determined using an MTT assay kit (Roche, Mannheim, Germany) 
according to the manufacturer’s protocol. Briefly, Swiss 3T3 cells in 96-well plates 
were treated as indicated and 10 µl of MTT labeling reagent was added to each well, 
after which the plates were incubated for 4 h. The cells were then incubated in 100 µl of 
the solubilization solution for 12 h, and the absorbance was measured with a microtiter 
plate reader (Bio-Rad, CA, USA) at a test wavelength of 550 nm and a reference 
wavelength of 650 nm. Percent viability was calculated as (OD of drug-treated 
sample/control OD) X 100. 
 
3.2.5.2 Crystal violet assay 
 
Cell viability was measured by crystal violet assay, which is based on preservation 
of crystal violet dye by healthy cells. Briefly, after treatments as indicated in the 
legends, cells were washed with phosphate buffered saline, fixed with methanol for 5 
min and stained for 10 min with 1.5% crystal violet solution. The dye was eluted with 
0.1 mol/l trisodium citrate and in ethanol for 1 hour and optical density was measured at 
630 nm. The data were expressed as mean ± SEM of untreated control. 
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3.2.5.3 Triple staining microscopy 
 
For the determination of apoptosis using triple staining, cells were grown on glass 
bottom dishes in DMEM with 10% FBS. After confluency, cells were incubated with 
DMEM plus 0.2% FBS for 12 hours. After indicated treatments, cells were washed 3 
times with PBS and then fixed with 2% paraformaldehyde and stained with Acridine 
Orange (AO), Propidium Iodide (PI) and Hoechst dye (HO) and cell death/apoptosis 
were assessed using fluorescence microscopy. At least 400 cells were counted in 5 high-
power fields using Olympus BX51 microscope and data were expressed as expressed as 
mean ± SEM of control. 
 
3.2.5.4 Cell Death Detection ELISAPLUS 
For evaluation of apoptosis, a Cell Death Detection ELISAPLUS kit (Roche, 
Mannheim, Germany) was used according to the instructions of the manufacturer. This 
kit detects cytoplasmic histone-associated DNA fragments (mono- and 
oligonucleosomes) after induced cell death. Briefly, cells were washed with PBS and 
incubated with 200 µl of lysis buffer for 30 min and centrifuged for 10 min at 300g, and 
20 µl of the supernatant (cytoplasmic fraction) was assayed in the ELISA. The reaction 
was developed with a peroxidase system, and development of color was measured with 
a microtiter plate reader (Bio-Rad, Hercules, CA, USA) at a test wavelength of 405 nm 
and a reference wavelength of 490 nm. Results were determined as fold increases in 
absorbance over untreated control cells (enrichment factor). 
 
3.2.5.5 Fluorometric caspase assay 
 
The enzymatic activity of caspase-3 and caspase-9 was determined by using a 
caspase activation assay kit (Sigma, Darmstadt, Germany). 3T3 fibroblasts were treated 
as indicated, washed twice with ice-cold PBS and then resuspended in lysis buffer [250 
mM HEPES, pH 7.4, 25 mM CHAPS, 25 mM DTT]. After 15 minutes of incubation on 
ice, samples were centrifuged for 10 minutes at 10000g at 4ºC, supernatants were 
collected and protein concentrations were determined by Bradford protein assay. Ten µg
of protein were assayed in 200 µl of reaction solution containing Ac-DEVD-AMC for 
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caspase-3-like DEVDase activity and Ac-LEHD-AMC for caspase-9 activity. The 
released fluorescent AMC was monitored at an excitation of 360 nm and emission of 
460 nm using a Spectramax Gemini XS multiplate spectrofluorometer (Molecular 
Devices, Sunnyvale, CA, USA). Results were calculated from a standard curve of AMC 
and specific caspase activities were derived as mean relative fluorescence units 
(RFU)/mg protein. The specificity of fluorometric caspase assays were always checked 
by inhibitor studies and internal positive controls. Data shown are mean ± SEM of three 
independent experiments performed in triplicate. 
3.2.6 Transfections 
 
Plasmid containing dominant form of c-Jun, pcDNAFLAG-D169 (c-JunD169; 
DN-c-Jun) was kindly provided by Dr. J. Ham (University College London, UK) and 
was described before [121]. The DN-JNK1 [pcDNA3-Flag-JNK1-APF] construct was 
kindly provided by Dr. R. Davis (Howard Hughes Medical Institute, Cambridge, MA, 
USA) and has the tyrosine 185 and threonine 183 amino acids, which require 
phosphorylation for activity replaced with alanine and phenylalanine, respectively. The 
empty pcDNA1 and pcDNA3 vectors were used as mock transfections and were 
purchased from Invitrogen (Gronmgen, the Netherlands). For transient transfections, 
Swiss 3T3 fibroblasts were plated in 60-mm dishes and transfected with plasmids (2–4 
µg) using Lipofectamine Plus reagent (Gibco Europe, Breda, the Netherlands) 
according to the manufacturer’s recommendations. The transfection medium was 
removed and replaced with fresh culture medium after 4 h, and the cells were incubated 
for another 16 h prior to treatments. The transfection efficiency was monitored via 
detection of FLAG-tag by immunofluorescence and immunoblot analysis. 
3.2.7. Statistical Analysis 
 
The results are expressed as mean ± SEM and the mean values were compared 
using Students t-tail test or one-way ANOVA analysis. Values of P<0.05 and P<0.01 
were considered statistically significant. 
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CHAPTER 4 
4 RESULTS 
 
4.1 Determination of HNE-induced cytotoxicity 
 
Although reactive oxygen species can cause cell death via apoptosis in many cell 
types and a number of antioxidants can block this effect, the molecular events. 
Molecular and genetic mechanisms activated in response to oxidative stress however are 
poorly understood. A number of reactive aldehydes originating from lipid peroxidation 
once have been formed induce severe cellular stress, including chromosome aberrations, 
sister chromatid exchanges, point mutations and cell killing. 
 
Recently, considerable attention has been paid to HNE because of its potential as 
a second messenger and a direct mediator in the intracellular signaling network. The 
present results show that HNE at could trigger cell death in quiescent Swiss 3T3 
fibroblasts in a dose-dependent manner (Figure 4.1). These cells are well characterized 
at the intracellular signaling level and can be reversibly arrested in the Go phase of the 
cell cycle thus removing the heterogeneity of response that may exist in an 
asynchronous population. In Figure 4.1A, cell viability has been determined by crystal 
violet assay and physiologically relevant doses of HNE can significantly affect viability 
of cells dose dependently. Concentrations above 50 µM of HNE induce gross non-
specific cytotoxicity and are not involved in further experiments. Results are further 
confirmed by differential staining (Hoechst dye, AO, PI) of the cells treated with 1–50 
µM HNE for 24 h, which indicates that cell death induced by HNE is mainly apoptotic 
(Figure 4.1B).  HO has access to altered apoptotic nuclei, which allows labeling cells 
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from early to late apoptotic stage. AO exerts preference for normal nuclei AT-rich 
regions and PI can enter only late apoptotic and necrotic cells through intercalating 
nucleic acids without sequence preference. Thus, triple staining is generally a preferred 
method to discriminate healthy, early/late apoptotic and necrotic cells in a culture.  
Apoptotic cell death is an active physiological process distinct from necrosis and is 
characterized by defined morphological and biochemical features including membrane 
blebbing, cytoplasmic shrinkage, chromatin condensation and DNA fragmentation. 3T3 
fibroblasts incubated with HNE for 24 h were apoptotic and the nuclei showed 
characteristic diffuse granular staining with HO (Figure 4.2). Under these conditions 
HO stained nuclei were highly fluorescent and appeared pyknotic. 
 
4.2 Protective effect of resveratrol against HNE-induced cytotoxicity 
 
There is a growing interest in compounds present in human diet with antioxidant 
properties and with different biological activity, including cardioprotective and cancer 
chemopreventive action. Among them, polyphenols and vitamins are considered as 
pioneering compounds among these small molecules. Resveratrol is a natural molecule 
with antioxidant, anti-fungal, anti-inflammatory, anti-platelet and anti-cancer action. 
Here we investigated the possible protective effect of resveratrol on HNE-induced 
apoptosis in 3T3 fibroblasts. The results indicate that HNE-induced apoptosis could be 
prevented by 4 hours pretreatment of the cells with resveratrol in a dose dependent 
manner (Figure 4.3). The most effective concentration of resveratrol is between 20-50 
µM. When we used resveratrol concentrations above 50 µM, it exerts further cytotoxic 
effects either alone or along with HNE treatment. Physiological level of resveratrol in 
plasma is very low and depends mainly on grapes and wine consumption. It has been 
shown that plasma level of resveratrol is about 5 µg/ml after 30-min drank of 100 ml 
wine containing 25 mg of resveratrol. The drug kinetic studies have shown that 
concentrations of resveratrol between 4.2-26 µM could be reached by nutrition. 
Thereby, we have used 20-50 µM of resveratrol in further experiments for the 
evaluation of molecular and cellular mechanisms of protective effects of resveratrol. 
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Figure 4.1 HNE induced apoptosis and cytotoxicity in fibroblasts. 3T3 cells were 
treated with indicated concentrations of 4-HNE for 24 hours. A: Cells were fixed and 
stained by 1.5% crystal violet for assessment of cell viability. The data are expressed as 
mean ± SEM % of untreated control and representative of six experiments. * P < 0.05,
** P < 0.01. B: Cells were fixed and stained with AO, HO and PI and healthy, necrotic 
and early/late apoptotic cells were scored as described in Materials and Methods. In 
each case, at least 400 cells were counted in 5 different microscopic fields. Data are 
expressed as mean ± SEM representative of six experiments. * P < 0.05, ** P < 0.01.
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Figure 4.2 Analyses of apoptosis using Hoechst staining. HNE induces apoptosis. 3T3 
cells grown on Glass Bottom Culture Dishes were treated with 50 µM of HNE for 24 
hours, fixed and stained with Hoechst 33342. Cells were visualized by using Olympus 
Fluorescence Microscope at 40X magnification. A: Control, B: HNE-treated cells. 
Arrows indicate fragmented nuclei and condensed chromatin. 
 
Figure 4.3 Protective role of resveratrol. Resveratrol prevents Swiss 3T3 fibroblast cell 
death and apoptosis. Cells were pretreated with indicated concentrations of resveratrol 
for 4 hours and then consequently treated with 50 µM HNE for 24 hours. Cells were 
fixed, stained with AO, HO and PI and healthy, necrotic, early and late apoptotic cells 
were scored as described in Materials and Methods. The data are expressed as mean ±
SEM and representative of six experiments.* P < 0.05, ** P < 0.01.
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One of the hallmarks of apoptosis is the endonuclease-mediated degradation of 
chromatin giving rise to DNA laddering. To investigate the effect of HNE and the role 
of resveratrol on DNA, laddering cells were incubated with HNE alone or pretreated 
with resveratrol. Cells treated with differing doses of HNE alone contained low 
molecular weight DNA species that migrated as a ladder with fragments differing by 
approximately 200 bp (Figure 4.4A). Pretreatment with resveratrol again prevented 
DNA laddering in a dose-dependent manner, where high molecular weight DNA was 
clearly observable (Figure 4.4B). 
 
Figure 4.4 Resveratrol protects against HNE-induced apoptosis. Resveratrol prevents 4-
HNE induced DNA fragmentation and apoptosis in a dose-dependent manner. A: 3T3 
cells were treated with indicated concentrations of HNE for 24 h. DNA was isolated, 
resolved on 1.5% agarose gel and visualized by staining with ethidium bromide. B: 3T3 
cells were pretreated with indicated concentrations of resveratrol for 4 h and then 
treated by 50 µM of HNE for 24 h. DNA was isolated, resolved on 1.5% agarose gel 
and visualized by staining with ethidium bromide. 
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4.3 Determination of HNE-induced ROS production 
 
The effect of HNE on the redox state of cells was determined with the fluorescent 
probe DCF-DA as shown in Figure 4.5. The results indicate that 2 hours incubation with 
50 µM HNE induced an increase in ROS intracellular level. At subtoxic concentrations 
and as low as 5–10 µM HNE is able to increase the production of ROS which again 
could be overcome by resveratrol (data not shown). In parallel, the antioxidant 
resveratrol prevented the HNE-induced increase in ROS again dose dependently (Figure 
4.5). Resveratrol acts as an antioxidant via free radical scavenging or direct interference 
with enzymatic systems involved in hydrogen peroxide production; which remains to be 
elucidated. Our data concerning the ROS level are consistent with previous works 
indicating that HNE increased the production of superoxide and hydroxyl radicals in 
neutrophils. Detection of ROS as early as 2 hours of incubation with HNE suggests an 
early response or a primary event leading to apoptosis. Although there are the HNE-
detoxifying enzymes; such as the GSH transferase, one can suggest that HNE through 
its reactions with cellular thiols can induce alterations in cellular oxidative status. It may 
well be suggested that HNE accumulated in mitochondria can alter mitochondrial 
functions and trigger free radical generation. In fact, cytochrome c release has been 
detected in cells undergoing apoptosis.  
 
4.4 HNE-induced modulation of c-Jun Expression/Phosphorylation, c-Fos 
expression and AP-1 Binding 
 
To investigate the effect of HNE on AP-1 proteins in 3T3 fibroblasts, we 
evaluated the levels of c-Jun, phospho-c-Jun, and c-Fos proteins. This event could be 
the first signal that might be highly relevant to the onset of the stress response 
represented by the induction of immediate early genes. As shown in Figure 4.6A, HNE 
(20 µM) dramatically stimulated the expression of c-Jun protein in a time-dependent 
manner with a maximal response by 1 h; in addition, increased phospho-c-Jun levels 
were detected at 1 h following HNE treatment. The increased expression of c-
Jun/phospho-c-Jun was sustained until 4 h after treatment. In contrast, time-course 
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experiments up to 4 h have shown that downregulation of c-Fos by HNE (20 µM) was 
evident at 30 min and remained downregulated until 4 h. Furthermore, the effect of 
HNE on AP-1 c-Jun, phospho-c-Jun, and c-Fos was concentration-dependent, in which 
HNE at 20 lM concentration induced increased c-Jun and phospho-Jun, and decreased 
c-Fos levels efficiently after 1 h of treatment (Figure 4.6A).  Our data indicate that 
induction of AP-1 proteins by HNE is highly specific to c-Jun. Because c-Jun is the 
major constituent of the transcription factor AP-1, and because HNE increased the 
expression of this proto-oncogene, we tested the effect of HNE on AP-1 activation.  AP-
1 activity was measured by its ability to bind to the palindromic TPA response element 
(TRE). The nuclear extracts of HNE-treated cells displayed greater binding activity than 
extracts of untreated cells, as determined by gel shift assay. The maximum increase in 
AP-1 binding activity in response to HNE (20 µM) treatment was observed by 1 h, and 
these responses persisted for at least 2 h (Figure 4.6B). HNE also induced a dose-
dependent activity in AP-1 binding, and an increased AP-1 binding could be observed 
with as little as 5 µM HNE treatment for 1 h. A clearly significant degree of binding 
was detected when cells were treated with 20 µM HNE for 1 h as compared to control 
untreated cells (Figure 4.6B). These results suggest that HNE induces activation of AP-
1 transcription factor complexes along with increased expression and phosphorylation 
of c-Jun and decreased expression of c-Fos.  
 
4.5 HNE-induced modulation of MAP kinases 
 
A number of transcription factors such as c-Jun/AP-1 and c-Fos/AP-1 have been 
shown to be phosphorylated by distinct members of MAP kinase proteins triggered by a 
large variety of extracellular stresses [81]. Based on the finding that HNE is a potential 
inducer of c-Jun expression and phosphorylation, a possible involvement of MAP 
kinases in HNE-induced c-Jun expression/phosphorylation was examined. To determine 
the possibility that HNE treatment of the cells results in the activation/phosphorylation 
of MAP kinases, whole cell lysates were probed with the antibodies specific for JNK, 
phospho-JNK, p38, phospho-p38, ERK 1/2, phospho-ERK 1/2 by means of immunoblot 
analysis.  
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Figure 4.5 Protective role of resveratrol against HNE-induced ROS formation. 
Fibroblasts grown on Glass Bottom Dishes treated with 50 µM 4-HNE for 2 h with or 
without pretreatment with indicated concentrations of resveratrol. Cells were 
subsequently stained by ROS sensitive fluorescence probe DCHF-DA and visualized by 
Olympus fluorescence microscope at 40x magnification. Relative fluorescence 
intensities for each condition were determined as pixel intensity for relative 
fluorescence quantification and classified into four brightness categories as percentage 
of total number of cells.  
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As shown in Figure 4.7, HNE (20 µM) induced an abrupt increase in 
phosphorylation of JNK, which peaked at 15 min after stimulation without any 
significant change in total JNK protein levels. The activity of JNK began to diminish at 
1 h of HNE treatment and became undetectable at 4 h. Interestingly, ERK 1 
phosphorylation became undetectable after 30 min of HNE treatment, but we were able 
to observe phosphorylated ERK 2 until 2 h after HNE stimulation. HNE induced a 
complete inhibition of ERK 1/2 phosphorylation after 2 h of treatment without any 
significant change in total ERK 1/2 protein levels. Immunoblot analysis of phospho-p38 
proteins revealed an early and transiently increased level of phospho-p38, which could 
be exclusively detected at 15–30 min after HNE treatment. HNE did not influence the 
total p38 protein level, as shown in Figure 4.7. In addition, loading of proteins for all 
immunoblots were checked by reprobing of membranes by -actin antibody; a 
representative -actin blot is shown in lower panel of Figure 4.7. These findings 
demonstrate that HNE alternates the activity of all three MAP kinases in 3T3 fibroblasts 
with different time kinetics and characteristics. 
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Figure 4.6 HNE-induced modification of c-Jun, c-Fos and AP-1 DNA binding. HNE 
modulates c-Jun and c-Fos proteins and AP-1 activation in Swiss 3T3 cells. 3T3 cells 
were grown on 60 mm culture flasks (1x 107 cells/well) and treated with 20 µM HNE 
for 0-4 h or treated with 0, 1, 5, 10 and 20 µM HNE for 1 h. A: Total protein lysates 
were isolated and c-Jun, phospho-c-Jun and c-Fos levels were detected by immunoblot 
analysis using specific antibodies. -actin was probed as a loading control for 
immunoblots and results are representative of three independent experiments. B: 3T3 
cells were grown on 6-well culture plates (1 x 106 cells/well) and treated with 20 LM 
HNE for 0-4 h or treated with 0, 1, 5, 10 and 20 µM HNE for 1 h. Nuclear proteins were 
isolated and gel shift assays were performed using 32P-labelled AP-1 oligonucleotide 
probe. Black arrows indicate the specific AP-1 complex. 
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Figure 4.7 HNE-induced regulation of MAP kinases. 3T3 cells were grown on 60 mm 
culture flasks (1x 107 cells/well) and treated with 20 µM HNE for 0-12 h. Activities of 
JNK, p38 and ERK 1/2 MAP kinases were detected by immunoblot analysis. Specific 
antibodies against total and phospho-JNK, total and phospho-p38 and total and 
phospho-ERK 1/2 were used for immunoblot analysis. -actin was probed as a loading 
control for immunoblots and results are representative of three independent 
experiments. 
 
4.6 Effect of HNE on caspase activation and cytochrome c release from 
mitochondria 
 
To identify the possible role of caspases in this apoptotic process, we investigated 
the  activation of caspase-9 and caspase-3 in response to HNE treatment by using 
immunoblot analysis for active caspase fragments and fluorometric caspase assays. 
HNE (20 µM) induced the appearance of an active caspase-9 fragment (35 kDa) at 1 h, 
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which was followed by a more evident and strong band in immunoblot analysis at 4–8 h 
after HNE treatment (Figure 4.8). The parallel analysis of caspase-9 activation through 
its ability to cleave its specific substrate (Ac-LEHD-AMC) and formation of the 
fluorogenic AMC compound displayed a quite different caspase-9 activation pattern 
compared to immunoblot analysis (Figure 4.8). Although we could detect a pronounced 
active caspase-9 band at 4 h of HNE treatment, a complete activation of caspase-9 
activation could only be detected at 8 h of HNE treatment in fluorometric caspase 
assays. In the mitochondrial apoptosis pathway, caspase-3 operates downstream of 
cytoplasmic cytochrome c translocation and caspase-9 activation. As shown in Figure 
2B, HNE (20 µM) induced the appearance of cleaved active caspase-3 fragments within 
4 h, and complete active bands were detected at 8 h posttreatment. The fluorometric 
caspase assays of caspase-3 activation through its ability to cleave its specific substrate 
(Ac-DEVD-AMC) and formation of the fluorogenic AMC compound presented a time-
course similar to immunoblot analysis for caspase-3 activation (Figure 4.8).  
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Figure 4.8 HNE-induced activation of caspases 3 and 9. 3T3 cells were grown on 6-
well culture plates (1x 106 cells/well) and treated with 20 µM HNE for 0-12 h. The 
activation of caspase-9 and caspase-3 were evaluated by immunoblot analysis and 
fluorometric caspase assays. For immunoblot analysis antibodies against active caspase-
9 and pro/active-caspase-3 were used and -actin was probed as a loading control. In 
caspase assays, results were expressed as mean ± SEM from three independent 
experiments performed in triplicate. 
 
The release of cytochrome c from mitochondria in response to apoptosis inducers 
(such as chemotherapeutics, UV radiation, growth factor withdrawal) and its binding to 
Apaf-1 leads to formation of apoptosome complex and caspase-9 activation [18]. As 
shown in Figure 4.9, HNE treatment resulted in an early and complete release of 
cytochrome c from mitochondria and its appearance in cytoplasm 1 h after HNE 
treatment, which is compatible with caspase-9 and caspase-3 activation patterns. Taken 
together, these results present evidence for intrinsic mitochondrial apoptotic machinery 
involved in HNE-induced apoptosis. 
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Figure 4.9 HNE-induced cytochrome c release. 3T3 cells were grown on 6-well culture 
plates (1x 106 cells/well) and treated with 20 µM HNE for 0-12h. The mitochondrial and 
cytoplasmic fractions of cytochrome c were detected by immunoblot analysis. CoxIV 
and -actin were probed as a loading control for mitochondrial and cytoplasmic 
fractions respectively. Results are representative of three independent experiments. 
 
4.7 JNK and caspases are functionally involved in HNE-induced apoptosis; 
protective effect of resveratrol 
Activation of MAP kinases either upstream or downstream of caspase has been 
postulated in many in vitro and in vivo experimental apoptosis models [80,87]. 
Regarding HNE-induced modulation of MAP kinases and caspases, we investigated the 
functional involvement of MAP kinases in HNE-induced apoptosis. It has been 
previously reported that HNE-induced cell death is predominantly apoptotic rather than 
necrotic Therefore, we utilized MTT assay for determination of cell viability in 
response to specific MAP kinase or caspase inhibitors and HNE treatment. Treatment of 
cells with HNE (20 µM) reduced cell viability to 37.39 ± 1.68% (Figure 4.10, lane 1), 
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and pretreatment of cells with 10 µM SP600125 (JNK inhibitor) for 1 h protected 3T3 
fibroblasts against HNE-induced apoptosis (Figure 4.10, lane 2, ** P < 0.01, compared 
to HNE-treated cells), but 10 µM SB203580 (p38 inhibitor) or 10 µM PD98059 (ERK 
1/2 inhibitor) did not exhibit any significant protective effect (Figure 4.10, lanes 3 and 
4, respectively). Pretreatment of cells with 20 µM pancaspase inhibitor Z-VAD-FMK 
(Figure 4.10, lane 5); 20 µM caspase-9 inhibitor, Z-LEHD-FMK (Figure 4.10, lane 6); 
or 20 µM caspase-3 inhibitor, Z-DEVD-FMK (Figure 4.10, lane 7) for 30 min 
significantly prevented HNE-induced apoptosis (**P < 0.01 for Z-VAD-FMK and Z-
LEHD-FMK; *P <0.05 for Z-DEVD-FMK, compared to HNE-treated cells). The 
protective effect of resveratrol (20 µM), a polyphenol with anti-carcinogenic and anti-
inflammatory properties, is also comparable to protective effects of SP600125 and 
caspase inhibitors (Figure 4.10, lane 8, ** P < 0.01, compared to HNE treated cells). 
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Figure 4.10 JNK and caspases are involved in HNE-induced apoptosis.3T3 cells were 
grown on 96-well plates (1 x 104 cells/well) and pretreated with specific MAP kinase 
and caspase inhibitors; (10 µM ERK 1/2 inhibitor (PD98059), 10 µM p38 inhibitor 
(SB203580) and 10 µM JNK inhibitor (SP600125) for 1 h; 20 µM pancaspase inhibitor 
(z-VAD-FMK), 20 µM caspase-9 inhibitor (z-LEHD-FMK), 20 µM caspase-3 inhibitor 
(z-DEVD-FMK) for 30 min and 20 µM resveratrol for 4 h, which is followed by 20 µM 
HNE treatment for 24 h. Cells treated with 20 µM HNE without inhibitor pre-treatment 
were also involved in experimental panels. The lanes for specific treatments are 
indicated in the figure. After incubation, the effects of specific kinase and caspase 
inhibitors on HNE-induced apoptosis were evaluated by MTT cell viability assay. MTT 
results are expressed as means ± SEM from three independent experiments performed in 
duplicate. (* P<0.05; ** P<0.01 compared with 20 µM HNE-treated sample) 
 
To determine the interdependency of MAP kinases and caspases, as well as to 
identify the critical steps involved in resveratrol-mediated protection against HNE-
induced apoptosis, we followed HNE-induced activation of caspases after pretreatment 
with specific MAP kinase inhibitors and resveratrol. As demonstrated in Figure 4.11, 
pretreatment of cells with 10 µM SP600125 or 20 µM resveratrol significantly inhibited  
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both caspase-3 and caspase-9 activation with similar efficiencies. In contrast, 10 µM 
SB203580 or 10 µM PD98059 did not confer any effect on caspase activation induced 
by HNE consistent with MTT results. Pretreatment of cells with caspase inhibitors did 
not show any effect on modulation of MAP kinases with HNE treatment (data not 
shown).  
 
We next explored the involvement of cytochrome c release in inhibitory effect of 
JNK and resveratrol on caspase activation. Figure 4.12 shows that pretreatment of cells 
with 10 µM SP600125 or 20 µM resveratrol led to blockage of cytochrome c release 
from mitochondria and thereby disrupted formation of the apoptosome complex and 
caspase-9 activation. Our results suggest a JNK-dependent caspase-activation module in 
HNE-induced apoptosis in which JNK acts upstream of mitochondrial apoptotic 
machinery and regulate cytochrome c release in response to HNE treatment. Resveratrol 
also acts upstream of mitochondrial apoptotic machinery and exerts its protective effect 
through prevention of cytochrome c release and consequent caspase activation. 
 
4.8 c-Jun/AP-1 transcriptional activity is involved in HNE-induced apoptosis 
 
The protective effect of a pharmacological inhibitor of JNK (SP600125) against 
HNE- induced apoptosis has put forth functional involvement of c-Jun/AP-1 activation 
for consideration in this process. To examine whether c-Jun/AP-1 activation has a 
similar role in HNE-induced apoptosis, we transfected 3T3 cells with the expression 
vector for DN-c- Jun mutant. DN-c-Jun mutant lacking the N-terminal c-Jun 
transactivation domain (amino acids 1–168) can efficiently dimerize, but it cannot 
activate transcription and will prevent any member of the Jun and Fos family from 
activating transcription of AP-1-dependent target genes and may do so by occupying 
AP-1 binding sites in the place of functional Jun/ Jun or Jun/Fos dimers. We also 
transfected 3T3 fibroblasts with the expression vector for DN-JNK1 to verify the 
protective effect of the pharmacological JNK inhibitor. The transfected cells were 
treated with HNE (20 lM) for 24 h and assayed for apoptosis using the Cell Death 
Detection ELISAPLUS kit. As shown in Figure 4.13, lane 3, overexpression of DN c-Jun 
significantly attenuated apoptosis when compared to HNE-treated untransfected cells 
(Fig. 4, lane 1), but the protective effect of DN-JNK1 overexpression against HNE-
induced apoptosis was more pronounced (Fig. 4.13, lane 5). The expression of mock 
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vectors did not exhibit any effect on HNE-induced apoptosis (Figure 4.13, lanes 2 and 
4). These results demonstrate that HNE-induced apoptosis in 3T3 fibroblasts involve c-
Jun/AP-1 activation downstream of JNK, but JNK also has downstream targets other 
than c-Jun/AP-1. 
 
Figure 4.11 Modulation of HNE-induced caspase activation by MAP kinase inhibitors 
and resveratrol. 3T3 cells were grown on 6-well culture plates (1x 106 cells/well) and 
pretreated with specific MAP kinase and caspase inhibitors 10 µM ERK inhibitor 
(PD98059), 10 µM p38 inhibitor (SB203580), 10 µM JNK inhibitor (SP600125) for 1 h 
and 20 µM resveratrol for 4 h, which is followed by 20 µM HNE treatment for 8 h. The 
activation of caspase-9 and caspase-3 were evaluated fluorometric caspase assays. 
Results are expressed as means ± SEM from three independent experiments performed 
in duplicate. (** P<0.01 compared with 20 µM HNE-treated sample.) 
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Figure 4.12 Modulation of HNE-induced cytochrome c release by resveratrol and JNK 
inhibitor SP600125. 3T3 cells were grown on 6-well culture plates (1x106 cells/well) 
and pretreated with 10 µM JNK inhibitor (SP600125) for 1 h and 20 µM resveratrol for 
4 h, which was followed by 20 µM HNE treatment for 8 h. The mitochondrial and 
cytoplasmic fractions of cytochrome c were detected by immunoblot analysis. CoxIV 
and -actin were probed as a loading control for mitochondrial and cytoplasmic 
fractions respectively. Results are representative of three independent experiments. 
 
4.9 Resveratrol inhibits HNE-induced JNK and p38 Activation, c-Jun 
expression, and phosphorylation 
 
To address the mechanisms of protection by resveratrol against HNE-induced 
apoptosis, 3T3 cells were pretreated with or without resveratrol (1, 10, or 20 µM) for 4 
h, followed by treatment with HNE (20 µM). Total protein lysates were analyzed for 
phosphorylation and expression of MAP kinases and c-Jun and expression of c-Fos by 
means of immunoblot analysis. Resveratrol attenuated HNE-induced JNK activation/ 
phosphorylation in a dose-dependent manner, and it completely blocked HNE-induced 
p38 activation/phosphorylation at 20 µM concentration without any effect on total JNK 
and p38 levels (Figure 4.14). Resveratrol also restored basal ERK 1/2 
activation/phosphorylation downregulated by HNE without any effect on total ERK1/2 
protein level (Figure 4.14). Immunoblot analysis also revealed that resveratrol 
pretreatment efficiently inhibited HNE-induced increase in c-Jun expression, even at the 
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10 µM concentration, but HNE-induced phospho-c-Jun levels could only be attenuated 
when cells were pretreated with 20 µM resveratrol (Figure 4.14). Resveratrol 
pretreatment also restored c-Fos protein level, which was downregulated by HNE 
treatment. Although a moderate effect of resveratrol was observed even at 1 µM 
concentration, a complete restoration of c-Fos protein levels similar to untreated cells 
could be achieved when cells were pretreated with 20 µM resveratrol (Figure 4.14). 
These results suggest that resveratrol could protect against HNE-induced apoptosis 
through alteration of cellular signaling modules formed by MAP kinases and their 
downstream targets. 
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Figure 4.13 Effect of dominant negative JNK1 and c-Jun expression on HNE-induced 
apoptosis. Modulation of HNE-induced apoptosis in 3T3 cells by transfection of DN-c- 
Jun and DN-JNK1. 3T3 fibroblasts were plated in 60 mm dishes and transfected with 
DN-c-Jun and DN-JNK1 plasmids. In order to evaluate the effect of DN-c-Jun and DN 
JNK1 overexpression on HNE-induced apoptosis, Cell Death Detection ELISAPLUS kit 
was used. The empty pcDNA1 and pcDNA3 vectors were used as mock transfections. 
Results are expressed as fold increases in absorbance over untreated control cells 
(enrichment factor) and means ± SEM from four independent experiments performed in 
duplicate. (* P<0.05; ** P<0.01 compared with 20 µM HNE-treated sample). 
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Figure 4.14 HNE-induced modification of MAP kinases, c-Jun, phospho-c-Jun and c-
Fos is altered by resveratrol pretreatment. 3T3 cells were grown on 6-well culture plates 
(1x 106 cells/well) and pretreated with 20 µM resveratrol for 4 h, which is followed by 
20 µM HNE treatment for 15 min to detect JNK and p38 activation, 4 h for ERK 1/2 
activation and 1 h for c-Jun, phospho-c-Jun and c-Fos levels. Total proteins were 
isolated and analyzed by means of immunoblot. -actin was probed as a loading control 
for immunoblots and results are representative of three independent experiments. 
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4.10 Modulation of HNE-induced AP-1 activation by SP600125 and 
resveratrol 
 
To examine whether AP-1 activation is a target for resveratrol, we evaluated the 
effect of resveratrol on HNE-induced AP-1 activation. 3T3 cells were pretreated with 
resveratrol (1, 5, 10, 15, or 20 µM) for 4h, followed by HNE (20 µM) for 1 h, and 
nuclear proteins were analyzed by means of AP-1 gel shift assay. Resveratrol dose-
dependently inhibited HNE-induced AP-1 activation with a maximum efficiency at 20 
µM concentration, and resveratrol (20 µM) alone did not trigger any significant effect 
on AP-1 activation (Figure 4.15). Because MAP kinases reside upstream of AP-1 
activation, we next investigated the inhibitory potential of specific MAP kinase 
inhibitors on AP-1 activation compared to resveratrol. Pretreatment of cells with 
SP600125 (10 µM) prior to treatment with HNE (20 µM) attenuated AP-1 activation at 
a comparable efficiency to resveratrol (20 µM) (Figure 4.15, lanes 4 and 3, 
respectively). In contrast, SB203580 (10 µM) and PD98059 (10 µM) did not exhibit any 
prominent effect on HNE-induced AP-1 activation (Figure 4.15, lanes 5 and 6, 
respectively). The specificity of AP-1 band was confirmed by competition experiments 
with an excess of unlabeled AP-1 oligonucleotide probe (Figure 4.15, lane 7), and by 
the ability of highly specific antibodies directed against individual AP-1 proteins to 
deplete nuclear extracts of DNA-binding activities, which confirmed that AP-1 
complexes are mainly formed by c-Jun/c-Jun dimers (Figure 4.15, lanes 8, 9, and 10). 
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Figure 4.15 Effect of resveratrol and MAP kinase inhibitors on HNE-induced AP-1 
activation. (A) 3T3 cells were grown on 6-well culture plates (1 x 106 cells/well) and  
pretreated with 1, 5, 10, 15 and 20 µM resveratrol for 4 h and consequently treated with 
20 µM HNE for 1 h. Cells treated with 20 µM HNE for 1 h without resveratrol 
pretreatment or treated 20 µM resveratrol alone for 4 h were also involved in 
experimental panels. Nuclear proteins were isolated and gel shift assays were performed 
using 32P-labelled AP-1 oligonucleotide probe. Black arrows indicate the specific AP-1 
complex. (B) 3T3 cells were grown on 6-well culture plates (1 x 106 cells/well) and 
pretreated with 10 µM ERK inhibitor (PD98059), 10 µM p38 inhibitor (SB203580), 10 
µM JNK inhibitor (SP600125) for 1 h and 20 µM resveratrol for 4 h, which is followed 
by 20 µM HNE treatment for 1 h . The lanes for specific treatments are indicated in the 
figure. The specificity of AP-1 binding was examined by competition with the 50x 
excess unlabelled probe (Lane 7) and the composition of AP-1 bands were defined by 
supershift experiments using c-Jun antibody (Lane 8), non-specific IgG (Lane 9) and c-
Fos antibody (Lane 10). 
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4.11 Modulation of Bcl-2 proteins by HNE treatment 
 
Bcl-2 proteins are key regulatory proteins of apoptosis signaling, mainly acting on 
mitochondrial membrane regulating protein trafficking and permeability [66]. The 
actual mechanism by which the Bcl-2 proteins maintain or ablate the integrity of the 
outer mitochondrial membrane is still unclear. Based on the finding that HNE is a 
potential inducer of cytochrome c release and caspase activation, HNE-induced 
modulation of Bcl-2 protein family members was examined. Total protein lysates were 
analyzed for expression of anti-apoptotic proteins Bcl-2, Bcl-xL and pro-apoptotic 
proteins Bax, Bak and Bim by means of immunoblot analysis. As demonstrated in 
Figure 4.16A, HNE induced decreased Bcl-2 protein levels at 12 h of treatment, but it 
did not induce any alteration of Bcl-xL. In contrast, HNE induced increased Bax and 
Bak levels with a maximum effect at 4-8 h of treatment, which was first evident within 
2 h for Bax.   HNE also induced moderately increased Bim levels at 8 h of treatment, 
which returned to basal levels at 12 h. The results suggest that both anti-apoptotic and 
pro-apoptotic Bcl-2 protein family members are involved in HNE-induced apoptotic 
signaling. To determine whether resveratrol could exert any effect on HNE-mediated 
alterations in Bcl-2, Bax, Bak and Bim levels, a detailed immunoblot analysis panel was 
obtained. The results indicated that resveratrol could prevent HNE-induced decrease of 
Bcl-2 protein level and HNE-induced upregulation of Bax, Bak and Bim proteins 
(Figure 4.16B).  
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Figure 4.16 Modulation of Bcl-2 proteins by HNE: effect of resveratrol. (A) 3T3 cells 
were grown on 6-well culture plates (1 x 106 cells/well) and with 20 µM HNE for 0-12h. 
Total protein lysates were isolated and Bcl-2, Bcl-xL, Bax, Bak and Bim protein levels 
were detected by immunoblot analysis using specific antibodies. -actin was probed as 
a loading control for immunoblots and results are representative of three independent 
experiments. (B) 3T3 cells were grown on 6-well culture plates (1x 106 cells/well) and 
pretreated with 20 µM resveratrol for 4 h, which is followed by 20 µM HNE treatment 
for 12 h for Bcl-2, 4 h for Bax and Bak, and 8 h for Bim protein levels. Total proteins 
were isolated and analyzed by means of immunoblot. -actin was probed as a loading 
control for immunoblots and results are representative of three independent 
experiments. 
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CHAPTER  5 
 
5 DISCUSSION  
 
5.1 HNE induces apoptosis and ROS production in 3T3 fibroblasts: 
protection by resveratrol 
HNE is a lipid peroxidation end product of arachidonic and linoleic acids. 
Because of its relatively high lipophilicity, HNE tends to concentrate within cell 
membranes where reasonably reaches steady-state amounts over 10–5 M [195]. Further, 
HNE may readily pass across the cellular membranes to modify critical molecules such 
as proteins and DNA [146,196]. As mentioned before, HNE with its highly electrophilic 
carbon could directly form covalent adducts with histidine, lysine, cysteine, serine and 
tyrosine residues of proteins and thereby alternate their functions [146,195]. Increased 
levels of HNE adducts have been detected in various human pathologies, such as 
neurodegenerative disorders, atherosclerosis and chronic obstructive pulmonary disease 
[195].  
 
In the present study, we show that incubation of 3T3 cells with increasing 
concentrations of HNE results in decreased cell viability in a dose-dependent manner at 
24 h of treatment. This reduced viability of 3T3 cells either could be due to acute 
necrosis of fibroblasts or programmed cell death. Thereby, we further characterized the 
type of cell death using Triple staining or Hoechst dye staining under fluorescence 
microscopy. The experiments have shown that HNE-induced cell death is mainly 
apoptotic when concentrations between 1 and 50 µM have been used. The fibroblasts 
have undergone acute necrotic and non-specific cytotoxicity above 50 µM HNE 
concentrations. At cellular level, HNE has been shown to reduce intracellular 
glutathione levels and modulate intracellular signaling pathways [2,197]. Glutathione is 
one of the major cellular defense systems against oxidative stress and the reduction of 
glutathione by HNE could lead to production of reactive oxygen species. Consequently, 
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we have investigated HNE-induced ROS production in response to HNE treatment via 
utilization of a ROS-sensitive fluorescence probe. The fluorescence microscopic 
analyses have shown that HNE induced increased ROS production, which could be 
effectively repressed by resveratrol. These findings are concordant with the pro-
oxidative effect of HNE. 
 
Resveratrol is a phytoalexin, which is one of most widely distributed flavones in 
nature and highly found in grape skin and seed, mulberries and peanuts. Resveratrol has 
been shown to exert anti-inflammatory and anti-proliferative effects in various cellular 
systems [198]. The cardioprotective effect of resveratrol as an important constituent of 
red wine has been proposed to be responsible for the “French paradox”, which reflects a 
low incidence of cardiovascular diseases along with a diet rich in fat [199]. Apoptosis 
and inflammation has been shown to be involved in the pathogenesis of atherosclerosis 
and this anti-apoptotic effect of resveratrol may be involved in its protective function 
against atherosclerosis [200]. Recent reports have mainly demonstrated that resveratrol 
acts as a cancer chemopreventive molecule mainly acting through triggering of 
apoptosis. Resveratrol was shown to induce pro-apoptotic p53 pathway through 
activation of ERK 1/2 and p38 MAP kinases in a mouse epidermal cell line [201]. In 
contrast, resveratrol has been shown to suppress TNF-induced NF-B and AP-1 
activation and apoptosis [174]. Ischemia-reperfusion- and -amyloid-mediated cellular 
injuries were shown to be prevented by resveratrol pretreatment [173,202]. Our results 
here demonstrate that resveratrol could effectively prevent HNE-induced cytotoxicity 
and apoptosis at physiologically achievable concentrations. Interestingly, when we 
loaded 3T3 cells at concentrations higher than 50 µM, resveratrol could induce an 
additive, but not a synergistic pro-apoptotic effect with HNE. This important finding 
underlines the activation or inhibition of distinct cellular pathways in response to high 
or low dose resveratrol treatment including HNE-induced ROS production.  
 
An extrinsic pathway, which involves direct initiator cascades triggered by death 
receptors on cell surface and an intrinsic pathway, which involves mitochondria and 
intracellular death signals, characterize mammalian apoptosis cascades. HNE has been 
shown to induce either apoptosis or proliferation in a concentration-dependent manner. 
HNE, at concentrations of 1-2.5 µM stimulated proliferation in vascular smooth muscle 
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cells [203]. In contrast, HNE has been demonstrated to induce apoptosis in various cell 
types, which involves either intrinsic or extrinsic apoptosis pathways [204,205]. In spite 
of intense research conducted, the exact mechanisms, which are involved in HNE-
induced apoptosis, remained to be elucidated. In our hands, HNE at 20 µM
concentration efficiently induced apoptosis in 3T3 cells and after characterization of 
kinetics in HNE-induced apoptosis, we then tried to identify the apoptotic mechanisms 
involved in this apoptotic process. Here we show that HNE leads to the release of 
cytochrome c from mitochondria and caspase-9 and caspase-3 activation with kinetics 
similar to that for induction of apoptosis. Contrarily, we could not detect any activation 
of caspase-8, which indicates that HNE-induced apoptosis does not involve an extrinsic 
apoptosis pathway.  Similarly, we could not detect Smac/DIABLO release or caspase-2 
activation in response to HNE, which eliminates the possibility of an alternative 
mitochondrial apoptotic process or ER stress pathway. 
 
5.2 HNE-induced modulation of AP-1 activation 
 
AP-1 transcriptional activity has been demonstrated to be related to either 
apoptosis or proliferation in different cellular systems (Shaulian and Karin, 2002). 
Being the major component of transcription factor AP-1, c-Jun once activated can 
subsequently activate the transcription of several genes. The fact that c-Jun gene itself 
also contained an AP-1 element in its promoter indicates that phosphorylation of c-Jun 
allows signals in this pathway to be amplified. Activation of AP-1 is regulated by 
complex mechanisms, which consist of distinct effects on the preexisting AP-1 complex 
or on de novo synthesis of AP-1 subunits [81]. Another major member of the AP-1 
transcription factor protein complexes, c-Fos, has been proposed to be necessary for cell 
proliferation and cell cycle progression in response to growth factor stimulation 
[206,207]. In contrast, both c-jun and c-fos mRNa levels have been reported to increase 
in lymphocyte apoptosis [208,209]. In HL60 leukemia cells HNE-induced apoptosis has 
been shown to take place following JNK activation, c-Jun phosphorylation and AP-1 
activation, which could be attenuated by transfection of HL60 cells with glutathione S-
transferase isozymes [210]. Activation of AP-1 in response to HNE treatment has also 
been reported to occur through caspase activation in cultured rat cortical neurons [211]. 
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HNE has been shown to upregulate both c-Jun and c-Fos protein levels in aortic smooth 
muscle cells [203]. It was assumed that induction of protein kinases by HNE might 
cause activation of signaling pathways, which phosphorylated and activated c-Jun [157, 
212]. Additionally, inhibition of proliferation of HeLa cells by HNE has been 
demonstrated to be mediated by upregulation of c-fos gene expression [213]. The 
experimental evidence presented here indicated the involvement of HNE in AP-1 
activation, as shown by the phosphorylation and potent expression of c-Jun.  
Interestingly, in our experimental conditions HNE at 20 µM induced a moderate 
decrease in c-Fos protein levels. HNE has been shown to upregulate the transcription 
factor AP-1 in all cell types studied so far, including hepatocytes, neuronal cells and 
vascular smooth muscle cells [157,203,211]. In brief, our results have presented that 
HNE induced the activation of an AP-1 complex mainly formed by c-Jun/c-Jun dimers, 
which compatible with increased c-Jun and phospho-c-Jun levels and decreased c-Fos 
level. Thereby, HNE may concurrently activate a pro-apoptotic c-Jun-mediated pathway 
and de-activate an anti-apoptotic c-Fos-mediated pathway, which aggravates the 
apoptotic response of fibroblasts in response to HNE treatment.  
 
5.3 Mining the signaling pathways involved in HNE-induced apoptosis 
5.3.1 c-Jun and MAP kinases 
 
Amino-terminal phosphorylation of c-Jun at serines 63 and 73 has been reported 
to regulate both proliferation and stress-induced apoptosis [116]. Furthermore, 
overexpression of a dominant-negative c-Jun (DN-c-Jun) mutant with a cleaved N-
terminal fragment has been shown to attenuate neuronal apoptosis induced by survival 
factor withdrawal [121,214]. In contrast, DN-c-Jun gene transfer has also been 
demonstrated to inhibit vascular smooth muscle cell proliferation and neointimal 
hyperplasia [215]. Additionally, overexpression of wild type c-Jun has been shown to 
trigger an apoptotic response in 3T3 fibroblasts and human vascular endothelial cells 
[216,217]. Our results indicated a pro-apoptotic role for c-Jun/AP-1 activation by HNE 
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because transfection of 3T3 fibroblasts with a DN-c-Jun mutant significantly attenuated 
HNE-induced apoptosis in 3T3 fibroblasts.  
 
Since we had demonstrated the requirement of c-Jun in HNE-induced apoptosis, 
we investigated the activation of upstream MAP kinases, which are proline-directed 
protein kinases involved in regulation of critical cellular processes such as proliferation, 
cell cycle progression, gene expression and apoptosis. It has been implicated that ERK 
1/2, which are primarily activated in response to growth factor stimulation, are involved 
in process of cellular proliferation and differentiation. Whereas, JNK and p38 MAP 
kinases are characterized by their strong response to cellular stresses such as UV light, 
serum deprivation, DNA damaging agents and pro-inflammatory cytokines [218,219].  
In contrast, activated MAP kinases could remain unrelated to apoptotic process. It 
should be noted that multiple cellular and molecular parameters should be considered 
when defining a signal transduction pathway either pro-apoptotic or anti-apoptotic, such 
as magnitude and duration of the signal and origin of stimuli. MAP kinases were 
reported to be activated by reactive oxygen intermediates (ROI) and oxLDL, but the 
mechanisms by which ROI and lipid peroxidation end products activate MAP kinases 
are unclear and the precise molecular targets are yet to be identified [220]. Previous 
reports have shown differential regulation or activation of MAP kinase pathways by 
HNE. HNE-induced activation of JNK has been initially presented on hepatic stellate 
cells and direct modification of p46 and p54 isoforms of JNK has been demonstrated 
[221]. In addition, in hepatic stellate cells no alteration of ERK pathway or c-Fos 
protein level has been observed. In vascular endothelial cells, stimulation of cells with 
HNE resulted in activation of ERK 1/2, p38 and JNK MAP kinases [222]. Besides, 
HNE has been shown to induce significant phosphorylation of JNK and p38, but not 
ERK 1/2 in rat hepatic epithelial cells [157]. Interestingly, it has been demonstrated that 
HNE induced a strong activation of JNK in PC12 cells during HNE-induced apoptosis, 
while ERK 1/2 and p38 MAP kinases remained unaffected [156]. JNK3 has also been 
reported to mediate a caspase-dependent HNE-induced apoptotic pathway in 
sympathetic neurons [223]. Further, treatment of IMR-90 human lung fibroblasts with 
25 µM HNE markedly activated ERK 1/2 and p38 without any effect on JNK MAP 
kinases [224]. The present findings suggest that HNE leads to activation of JNK and 
p38 MAP kinases, but with different time kinetics and amplitudes. HNE (20 µM) led to 
a transient activation of p38 and an immediate increase of p-JNK levels, which reached 
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a maximum at 30 min. In contrast, phospho-ERK 1/2 down-regulation was induced at 
30 min following HNE treatment and no phospho-ERK 1/2 could be detected at 4 h 
following HNE treatment. An interesting finding, which was derived from dose-
dependent activation patterns of MAP kinases by HNE, was that activation of JNK and 
p38 kinases was induced maximally at 20 µM HNE concentration. The involvement of 
MAP kinases in HNE-induced apoptosis was evaluated using their specific inhibitors. 
Pretreatment with JNK inhibitor (SP600125) effectively prevented the apoptosis 
induced by 20 µM HNE. ERK inhibitor (PD98059) or p38 inhibitor (SB203580) 
pretreatment did not have any significant effect on the apoptosis induced by 20 µM 
HNE.  
 
In order to establish the molecular mechanisms of this differential MAP kinase 
involvement in HNE-induced apoptosis, we investigated the release of cytochrome c
and caspase-9 and caspase-3 activation by utilizing pretreatments with specific MAP 
kinase inhibitors before HNE stimulation. Pretreatment with JNK inhibitor prevented 
cytochrome c release and caspase activation by 20 µM HNE, which indicates that JNK 
acts upstream of mitochondria in the apoptotic signaling machinery. Furthermore, 
pretreatment of cells with JNK inhibitor prior to HNE stimulation attenuated AP-1 DNA 
binding activity, but we could not able to observe any significant effect with p38 or 
ERK 1/2 inhibitors. Additionally, overexpression of a dominant-negative JNK1 mutant 
efficiently inhibited HNE-induced apoptosis, which confirmed the involvement of JNK 
in HNE-mediated apoptosis in 3T3 fibroblasts. The protective effect of DN-JNK1 
overexpression was more pronounced than DN-c-Jun overexpression, which underlines 
JNK targets other than c-Jun in HNE-induced apoptotic pathway, such as Bcl-2 protein 
members. Interestingly, a recent report has proposed the involvement of the Bcl-2 
family member, Bim in c-Jun-mediated apoptosis and cytochrome c release in neuronal 
cells, which indicates c- Jun target genes that are involved in HNE-induced apoptosis 
should be identified [121,214].  
 
5.3.2 Protective mechanisms of resveratrol through JNK/AP-1 pathway 
 
To investigate the mechanisms of this protection by resveratrol, we further 
evaluated its effects on HNE-induced c-Jun/AP-1 activation. Resveratrol prevents 
increased c-Jun expression and phosphorylation, as well as AP-1 DNA binding activity 
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at a comparable efficiency with JNK inhibitor. It is noteworthy that HNE-induced p38 
and JNK activation could be inhibited efficiently by resveratrol. Resveratrol has also 
restored the decreased c-Fos and phospho-ERK 1/2 levels. The exact mechanism 
responsible for the inhibitory effect of resveratrol on HNE-induced JNK activation 
remained to be elucidated, but it is possible that resveratrol exerts its activity either by 
inhibiting upstream kinases of JNK such as protein kinase C (PKC) or by activating 
JNK-specific protein phosphatases. Additionally, caspase activation and cytochrome c
release from mitochondria have also been attenuated by resveratrol pretreatment. 
Considering the involvement of c-Jun/AP-1 and JNK pathway in HNE-induced 
apoptosis, resveratrol blocks the apoptotic machinery through inhibition of these 
pathways upstream of mitochondria.  Moreover, inhibition of HNE-induced ROS 
production may also be interpreted as a secondary mechanism regarding the protective 
capacity of resveratrol.  
 
5.4 HNE-induced apoptosis and Bcl-2 proteins 
 
The release of cytochrome c from mitochondria is regulated, in turn, through the 
activation of pro-apoptotic Bcl-2 protein family members, along with possible 
inactivation of anti-apoptotic Bcl-2 protein family members [12,33,60,66]. HNE-
induced apoptosis involves a mitochondria-dependent caspase activation cascade. 
Interestingly, there is little available data on HNE-induced modulation of Bcl-2 protein 
family members. Bcl-2 protein expression has been shown to protect against HNE-
induced apoptosis of PC12 cells induced by oxidative stress and HNE [225]. PC12 cells 
expressing Bcl-2 has been demonstrated to exhibit higher levels of glutathione and 
lower levels of HNE after oxidative stress [225]. Furthermore, Bcl-2 and 4-
hydroxynonenal modified proteins have been shown to colocalize in microglial cells 
and neurons of rat brain following transient focal ischemia [226]. Moreover, 
overexpression of anti-apoptotic protein Bcl-2 in stably transfected RAW 364.7 murine 
macrophages has been demonstrated to prevent HNE-induced internucleosomal DNA 
fragmentation and apoptosis [227]. Furthermore, constitutive expression of high levels 
of Bcl-2 protected cells from HNE-mediated apoptosis and inhibited cytochrome c 
release from mitochondria and subsequent caspase-2, -3, and -9 activation [228]. In our 
experimental system, HNE induced a prominent decrease in Bcl-2 levels, but we could 
not detect any alteration of Bcl-xL protein level. The decrease in Bcl-2 protein at a 
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delayed time point in HNE-induced apoptosis implied a late response role for Bcl-2 
against activated apoptotic machinery. The expression of Bcl-2 is mainly controlled by 
the transcription factor NF-B and HNE has been shown to downregulate NF-B
activation in various studies. Indeed, we were expecting an early upregulation of Bcl-2 
to prevent HNE-induced apoptosis. Thereby, this late response of Bcl-2 could be 
because of inhibition of NF-B and failure of Bcl-2-mediated anti-apoptotic response. 
HNE-induced Bax expression has been reported in SK-N-BE neuroblastoma cell line 
[229].  Our results have shown that HNE also induced increased pro-apoptotic Bax, Bak 
and Bim proteins. Bak -/- Bax -/- MEFs have been shown to be insensitive to multiple 
apoptotic stimuli including chemotherapeutics and UV radiation [60]. Furthermore, 
Bax-null cells have been shown to be resistant against receptor-mediated apoptosis [61]. 
Activation of caspase cascades by DNA damage and ER stress has been shown to be 
directly regulated by Bax and Bak in double knock-out MEFs [63]. The involvement of 
Bax and Bak in HNE-induced apoptosis is evident as the time kinetics of cytochrome c 
release and caspase activation is compatible with increased Bax and Bak proteins. Bim 
is a direct activator BH3-only protein, which interact with pro-apoptotic Bcl-2 proteins 
such as Bak and Bax and thereby induce their activation/oligomerization [66].  HNE-
induced  upregulation/activation of Bim could induce Bax or Bak activation, which 
could overcome the protective effect of Bcl-2 through selective sequestration and 
functional silencing. 
 
We further investigated the effect of resveratrol treatment on HNE-induced 
modulation of Bcl-2 proteins. The results have shown that resveratrol prevented HNE-
induced downregulation of Bcl-2 and upregulation of Bax, Bak and Bim. These results 
indicate that Bcl-2 protein members are among the targets of resveratrol in addition to 
JNK/AP-1 pathway. The modulation of upstream signaling pathways regulating the 
expression of Bcl-2 protein by resveratrol is a possible explanation for this phenomena, 
but the exact upstream molecular targets remain to be identified.  
 
The formation of Michael adducts with free thiol groups has been described as  
the main reaction of HNE. In addition to thiols, HNE could also presumably form 
Michael adducts with the imidazole moiety of histidine residues. By way of this 
reaction, the aromatic nitrogen of histidine could attack the olefinic moiety of HNE at 
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its  position just as with any Michael-addition to an ,-unsaturated carbonyl 
compound (Figure 5.1A).  
 
Figure 5.1 Proposed mechanisms of HNE-induced modification of histidine  
residues. (A) HNE could participate in a Michael addition reaction with the  
imidazole moiety of histidine residues. (B) HNE could react with the primary  
amine group histidine to form a Schiff base conjugate. 
 
HNE may also react with the primary amine group of histidine to form a  
Schiff base conjugate (Figure 5.1B). In principle, other products could also be  
formed, given appropriate conditions. For instance, it is possible to have a  
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Michael addition to an ,-unconjugated Schiff base or a double Michael adduct  
to histidine residues, affording a charged aromatic ring in the process. These  
direct modifications potentially have the ability of modulating cellular and  
molecular functionality of critical signaling proteins, which may be  
responsible for the cellular toxicity of HNE. 
 
While much work has been conducted on the consequences of HNE, surprisingly 
little effort has been directed at identifying the direct products of HNE reaction with 
proteins and other biological components. Perhaps the technical difficulties of such an 
undertaking have been one factor that has discouraged such investigations. At any rate, 
in light of the implications related to the work herein, it would follow to reason that the 
time has come to readdress the question as to which direct chemical derivatives are 
responsible for the cellular response. A radiolabeling approach might be one way to 
address this issue. For instance, tritiated or 14-C radiolabeled HNE could be incubated  
under the same conditions as non-radioactive HNE was used in the work conducted  
herein. The direct reaction products could then be isolated, chromatographically 
separated, located by autoradiography, and identified using appropriate standards 
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6 CONCLUSION 
 
In conclusion, we report here on the activation of apoptotic signaling pathways by 
HNE, which involves the activation of JNK-c-Jun/AP-1 signaling cascade, 
mitochondrial cytochrome c release and caspase-9/3 activation (Figure 6.1). 
Furthermore, involvement of Bcl-2 proteins in HNE-induced apoptosis is evident. As 
summarized in Figure 6.1, resveratrol prevents JNK, c-Jun/AP-1, caspase activation and 
apoptosis induced by HNE. Resveratrol also prevents HNE-induced downregulation of 
anti-apoptotic Bcl-2 protein and upregulation of pro-apoptotic Bax, Bak and Bim 
proteins. Thus, our studies provided a new insight into the molecular mechanisms of 
HNE-induced apoptosis and the cytoprotective properties of resveratrol.  
 
Figure 6.1 Proposed mechanisms of HNE-induced apoptosis signaling pathways and 
molecular targets of resveratrol in HNE-induced apoptotic cascades. 
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The present results argue strongly that c-Jun-mediated genes as well as direct JNK 
target proteins other than c-Jun/AP-1 pathway, which are involved in HNE-induced 
apoptosis, remained to be identified. The pro-apoptotic Bim has been proposed as a 
direct mediator of c-Jun-mediated apoptosis and it is also a potential mediator of HNE-
induced transcription-dependent apoptotic signaling. Moreover, identification of these 
mechanisms along with utilization small-molecule inhibitors such as resveratrol may 
enable the development of specific and rationale therapies against human diseases 
caused by deregulation of apoptosis. 
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APPENDIX A 
CHEMICALS 
(in alphabetical order) 
Name of Chemical       Supplier Company   Catalog Number 
Acetic acid                                       Sigma, Germany    A9967 
Acridine Orange                              Sigma, Germany A6014 
Acrylamide/Bis-acrylamide   Sigma, Germany    A3699 
 Biorad Inc., USA   161-0158 
Agarose low EO    Applichem, Germany   A2114 
Ammonium persulfate    Sigma, Germany    A3678 
Ampicillin     Sigma, Germany    A9518 
Antibiotic solution                           Sigma, Germany                              P3539 
Anti--actin Ab                              Santa Cruz Biotech, USA   sc-1616 
Anti-c-Jun Ab                                 Santa Cruz Biotech, USA   sc-044 
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Anti-p-c-Jun Ab                             Santa Cruz Biotech, USA    sc-046   
Anti-c-Fos  Ab                    Santa Cruz Biotech, USA                 sc-052 
Anti-JNK Ab                                  Cell Signal Tech., USA     9252 
Anti-p-JNK Ab            Cell Signal Tech., USA      9251 
Anti-ERK 1/2 Ab          Cell Signal Tech., USA    9102 
Anti-p-ERK 1/2 Ab                        Cell Signal Tech., USA   9101 
Anti-p38 Ab                                   Cell Signal Tech., USA    9212 
Anti-p-p38 Ab                                Cell Signal Tech., USA   9211 
Anti-caspase 9 Ab           Cell Signal Tech., USA    9505 
Anti-caspase 3 Ab                          Cell Signal Tech., USA   9665 
Anti-cytochrome c Cell Signal Tech., USA    4272 
Anti-CoxIV Ab                              Cell Signal Tech., USA    4844 
Bradford solution                            Biorad Inc., USA                              500-0001 
Chloroform    Merck, Germany    102431 
CM-H2DCF-DA    Molecular Probes, USA   C-6827 
Coomassie Brilliant Blue  Merck, Germany    115444 
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Crystal Violet                                   Sigma, Germany C3886 
Dulbecco’s MEM (DMEM)            Sigma, Germany D5546 
DMSO                                            Sigma, Germany D2650 
DTT      Sigma, Germany D9779 
EDTA      Riedel-de Haén, Germany  27248 
Ethanol     Riedel-de Haén, Germany  32221 
Ethidium Bromide   Merck, Germany    OCO28942 
Foetal Bovine Serum                      Sigma, Germany F2442 
Glycerol     Riedel-de Haén, Germany  15523 
Glycine     Amnesa, USA    0167 
HCl      Merck, Germany    100314 
Hepes     Sigma, Germany H7006 
Hoechst dye                                     Sigma, Germany B2883 
4-Hydroxynonenal                           Calbiochem, USA    393204 
Hyperfilm ECL     Amersham Biosciences, UK RPN2114K 
IPTG      Promega, Germany   V39517 
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Isopropanol    Riedel-de Haén, Germany  24137 
KCl      Fluka, Switzerland   60129 
KH2PO4 Riedel-de Haén, Germany  04243 
KOH      Riedel-de Haén, Germany  06005 
Liquid nitrogen    Karbogaz, Turkey 
Lipofectamine                                  Invitrogen, Germany                      18324020 
Luria Agar     Sigma,Germany    L-3147 
Luria Broth    Sigma, Germany    L-3022 
2-Mercaptoethanol   Sigma, Germany                           M370-1 
Methanol     Riedel-de Haén, Germany  24229 
MgCl2 Sigma, Germany M9272 
Milk Diluent concentrate                 KPL, USA 50-82-00 
NaCl      Riedel-de Haén, Germany  13423 
NaO2C2H3.3H2O Riedel-de Haén, Germany  25022 
NaOH     Merck, Germany    106462 
NaPO4H2 Riedel-de Haén, Germany  04269 
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NP-40     Sigma, Germany I3021 
PD98059     Calbiochem, USA    513000 
Phenol     Applichem, Germany   A1153 
Phenol/chloroform   Applichem, Germany   A0889 
/isoamylalcohol 
Phosphate buffered saline               Sigma, Germany     P4417 
PMSF      Sigma, Germany    P7626 
Poly dI/dC     Sigma, Germany P4929 
Propidium iodide                            Sigma, Germany     P4170 
Resveratrol                                      Sigma, Germany     R5010 
SB203580                                       Calbiochem, USA    559389 
SP600125       Calbiochem, USA    420123  
 
Sodium Dodecyl Sulphate  Sigma, Germany    L4390 
Sucrose     Sigma, Germany    S0389 
TEMED     Sigma, Germany    T7029 
Triton X-100    Applichem, Germany   A1388 
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Tris      Fluka, Switzerland   93349 
Tween® 20    Merck, Germany    822184 
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APPENDIX B 
MOLECULAR BIOLOGY KITS 
(in alphabetical order) 
Name of Kit            Supplier Company          Catalog Number 
ECL Advance Chemiluminescence  Amersham Biosciences , UK        RPN2135 
Detection Kit  
Cell Proliferation Kit I (MTT)                  Roche, Germany 1465007-001 
Cell Death Detection ELISAPLUS Roche, Germany 11774425-001 
Qiaprep® Spin Miniprep Kit (250)          Qiagen, Germany                             27106 
QIAGEN® Plasmid Midi Kit (100)  Qiagen, Germany   12145 
QIAGEN® Plasmid Maxi Kit (500)  Qiagen, Germany   12165 
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APPENDIX C 
OTHER MATERIALS 
(in alphabetical order) 
Name of material Supplier Company Catalog Number 
Hybond-P membrane (PVDF)      Amersham Biosciences, UK  RPN2020F 
Hyperfilm ECL          Amersham Biosciences, UK  RPN2103K 
Mass Ruler DNA Ladder,Mix       Fermentas, Germany            #SM0403 
(Agarose gel photograph and MW values of bands are provided below)    
Protein MW Marker          Fermentas, Germany   #SM0431 
(gel photograph and MW  values of bands are provided below) 
Prestained Protein MW Marker  Fermentas,Germany   #SM0441 
(gel photograph and MW  values of bands are provided below) 
RNase A      Roche, Germany   1119915  
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T4 kinase      Promega, Germany  M4103 
T4 DNA kinase Buffer (10X)  Promega, Germany  M4103-B 
TOP10      Invitrogen, Germany  C4040-03 
 
Mass Ruler DNA LadderMix 
 
1.0% agarose 
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Protein MW Marker    Prestained Protein Molecular Weight Marker 
12% SDS-PAGE, Coomassie Brilliant Blue R-250 stained 
Plasmids 
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APPENDIX D 
Autoclave: Hirayama, Hiclave HV-110, JAPAN 
 Certoclav, Table Top Autoclave CV-EL-12L, AUSTRIA 
Balance: Sartorius, BP211D, GERMANY 
 Sartorius, BP221S, GERMANY 
 Sartorius, BP610, GERMANY 
 Schimadzu, Libror EB-3200 HU, JAPAN 
Blot Module X Cell II ™ Blot Module, Novex, USA 
Centrifuge: Eppendorf, 5415C, GERMANY 
 Eppendorf, 5415D, GERMANY 
 Eppendorf, 5415R, GERMANY 
 Kendro Lab. Prod., Heraeus Multifuge 3L, GERMANY 
 Hitachi, Sorvall RC5C Plus, USA 
 Hitachi, Sorvall Discovery 100 SE, USA 
Deepfreeze: -70o C, Kendro Lab. Prod., Heraeus Hfu486 Basic, GERMANY 
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-20o C, Bosch, TÜRKOYE 
Distilled Water: Millipore, Elix-S, FRANCE 
 Millipore, MilliQ Academic, FRANCE 
Electrophoresis: Biogen Inc., USA 
 Biorad Inc., USA 
 X Cell SureLock ™ Electrophoresis Cell, Novex USA 
Gel Documentation: UVITEC, UVIdoc Gel Documentation System, UK 
 Biorad, UV-Transilluminator 2000, USA 
Ice Machine: Scotsman Inc., AF20, USA 
Incubator: Memmert, Modell 300, GERMANY 
 Memmert, Modell 600, GERMANY 
Laminar Flow: Kendro Lab. Prod., Heraeus, HeraSafe HS12, GERMANY 
Magnetic Stirrer: VELP Scientifica, ARE Heating Magnetic Stirrer, ITALY 
 VELP Scientifica, Microstirrer, ITALY 
Microliter Pipette: Gilson, Pipetman, FRANCE 
 Mettler Toledo, Volumate, USA 
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Microwave Oven: Bosch, TÜRKOYE 
pH meter: WTW, pH540 GLP MultiCal®, GERMANY 
Power Supply: Biorad, PowerPac 300, USA 
 Wealtec, Elite 300, USA 
Refrigerator: +4o C, Bosch, TÜRKOYE 
Shaker: Forma Scientific, Orbital Shaker 4520, USA 
 GFL, Shaker 3011, USA 
 New Brunswick Sci., Innova™ 4330, USA 
 C25HC Incubator shaker New Brunswick Scientific, USA 
Sonicator Vibracell 75043, Bioblock Scientific,FRANCE 
Spectrophotometer: Schimadzu, UV-1208, JAPAN 
 Schimadzu, UV-3150, JAPAN 
 Secoman, Anthelie Advanced, ITALY 
Speed Vacuum: Savant, Speed Vac® Plus Sc100A, USA 
 Savant, Refrigerated Vapor Trap RVT 400, USA 
Thermocycler: Eppendorf, Mastercycler Gradient, GERMANY 
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Vacuum: Heto, MasterJet Sue 300Q, DENMARK 
Water bath: Huber, Polystat cc1, GERMANY 
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Claims to original research and publications arising from this thesis 
 
1. First characterization of HNE-induced apoptosis signaling cascades in 3T3 
fibroblasts, including cytochrome c release, caspases, MAP kinases, AP-1 and 
Bcl-2 family proteins. 
 
2. First demonstration that JNK-c-Jun/AP-1 pathway is involved in HNE-induced 
apoptosis. 
 
3. First direct evidence that resveratrol could protect againts lipid peroxidation-
induced ROS production. 
 
4. First demonstration of  the protective effect of resveratol against HNE-induced 
apoptosis through modulation of MAP kinases, caspases and Bcl-2 proteins. 
 
5. First evidence that transcriptional activity of c-Jun is involved in HNE-induced 
apoptosis. 
 
Refeered publications arising from this thesis: 
 
1. Kutuk, O., Adli, M., Poli, G., Basaga, H. Resveratrol protects against 4-HNE 
induced oxidativestress and apoptosis in Swiss 3T3 fibroblasts. Biofactors, Vol 
20, Issue 1, 1-10, 2004. 
 
2. Kutuk, O., Poli, G., Basaga H. 4-Hydroxynonenal induces apoptosis through 
activation of JNK and c-Jun/AP-1: protection by resveratrol, Toxicological 
Sciences, Vol 90, Issue 1, 120-132, 2006. 
 
